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1Chapter 1
General introduction
2Scope of the project "T lymphocytes in inflammatory neuropathies"
This thesis deals with three subjects: inflammatory neuropathies, the (human) immune system,
and microbial pathogens. In the broadest sense, the goal of the work described in this thesis is to
reveil how activation of the immune system causes inflammatory neuropathy. This is a very
general description, but the work presented here is mainly focussed on one neuropathy, Guillain-
Barré syndrome (GBS), which is often induced by a bacterium called Campylobacter jejuni. The
part of the immune system that was concentrated on was restricted to the T cell response, which
resulted in a description of the presence of T cell-stimulatory molecules in neuropathy-affected
nerve, the T cell response against myelin, and the γδ T cell response to C. jejuni in healthy
subjects and GBS patients. The choice for the study of T cells in peripheral neuropathy made it an
unusual project in the field, since most work on the pathogenesis of GBS is concentrated on the
role of antibodies. The molecular mimicry hypothesis, which is based on structural resemblances
between Campylobacter and peripheral nerve constituents, and is supported by the presence of
cross-reactive antibodies in the serum of GBS, is currently dominating experimental GBS
research. Although one of the most sophisticated hypotheses in the field, there is no evidence that
it accurately describes the mechanism of pathogenesis of GBS. Since the formulation of this
hypothesis, research has narrowed down to the search for support for it, with the main goal being
the identification of a pathogenic, crossreactive antibody and the antigen it recognizes.
The scope of the project "T lymphocytes in inflammatory neuropathies" is the possible
involvement of T lymphocytes in the pathogenesis of inflammatory neuropathies. T lymphocytes
are the central theme in this thesis and the focus has been shifted deliberately from the
characterization of antibodies toward the role of T lymphocytes. In my opinion the most obvious
gap in the knowledge about inflammatory neuropathies is the absence of data concerning the role
of T cells during pathogenesis. In this thesis, the T cell response to myelin and to the microbial
pathogen C. jejuni, and the status of the T cells during inflammatory neuropathy will be
described. In the general discussion the newly obtained data will be put together into a hypothesis
on the pathogenesis of GBS.
The rest of this general introduction will describe clinical aspects of inflammatory neuropathies,
data on the status of the humoral and cellular immune system during inflammatory neuropathies,
correlation with infectious diseases, and current hypotheses of autoimmune pathogenesis.
Furthermore, the human γδ T lymphocyte will be introduced and placed in a context of basic
immunology.
3Inflammatory neuropathies
Damage to the axon or myelin sheath of the peripheral nerve leads to dysfunction called
neuropathy. In addition to toxic substances, metabolic disturbances, degenerative processes, and
physical damage, it is well recognized that components of the immune system can also be
involved in pathogenesis. If antibodies, complement, T cells, or macrophages are likely to be
involved in the pathogenesis of neuropathy, it is called an inflammatory or immune-mediated
neuropathy. Though the main focus of this thesis is on GBS, Chapter 2 and 3 include chronic
inflammatory demyelinating neuropathy (CIDP). A mayor clinical difference between CIDP and
GBS is the chronic course of CIDP versus the acute character of GBS. Acute onset of disease
means that the nadir is reached between a couple of days and 6 weeks, whereas chronic disease
may relapse and remit or worsen continually for months or years. Another way to classify
peripheral neuropathies is based on electrophysiological data. Damage to the myelin sheath can
be distinguished from damage to the axon. This distinction is of clinical interest, since damage to
myelin recovers better than axonal damage. A troubling factor is that primary axonal damage
leads to secundary demyelination and vice versa. The two primary axonal variants of GBS that
can be distinguished are Acute Motor Axonal Neuropathy (AMAN) and Acute Motor Sensory
Axonal Neuropathy (AMSAN), and a primary demyelinating form is Acute Inflammatory
Demyelinating Neuropathy (AIDP). In addition, there is a variant of GBS in which mainly the
cranial nerves are affected, called Miller Fisher syndrome (MFS).
GBS patients benefit from therapy with intravenous immunoglobulins (IvIg). Though GBS is a
selflimiting disease, trials with large amounts of patients have shown that the severity of the
disease is less if the patient is given IvIg. The working mechanism of this therapy is not
understood. Therapy given to CIDP patients consists of corticosteroids and/or immune
suppressive drugs like cyclosporin, cyclophosphamide, or dexamethasone, and also IvIg.
The immune system during inflammatory neuropathies
In rather few cases, biopsies and postmortem material of peripheral nerve of GBS patients were
studied. An infiltrate consisting of macrophages and lymphocytes has been described1, and also
the presence of complement activation products2. Material of CIDP patients is more easily
accessible and therefore the histopathology of this disease is much better studied, including the
presence of B cells and αβ and γδ T cells, and the Vβ chain expression of the infiltrating T cells3.
All available data concerning inflammatory neuropathy point to aspecific infiltration, which
4means that the T cell population present in peripheral nerve does not differ much from the
population in blood.
The study of affected nerve material provides a local morphological and immuno-phenotypical
description of a certain stage of a neuropathy. Additional data concerning the status of the
immune system have been obtained from blood of patients suffering from inflammatory
neuropathy. The circulating T lymphocyte population of CIDP patients has been shown to have a
higher frequency of mutations in the HPRT gene, which is an indication of frequent activation4.
Aberrant amounts of T lymphocyte-related cytokines in serum of GBS patients have been
described, like IL-25, γIFN6, TGFβ7, and IL-188, and increased levels of soluble IL-2 receptor9,
suggesting that T cell activation takes place during inflammatory neuropathy. The presence of
auto-antibodies has extensively been studied, especially antibodies recognizing the glycosylations
of glycolipids or glycoproteins that are present in peripheral nerve. Antibodies against the
gangliosides GM1 and GD1 occur frequently in GBS, and antibodies against GQ1 are found in
most cases of MFS. In CIDP and GBS, antibodies against P0 and P2 have been implicated10. A
primary pathogenic role for these antibodies has been tentatively proposed, but is hard to prove.
Moreover, not all patients have these antibodies, and not all people with these antibodies suffer
from neuropathy, so if they play a role in pathogenesis, it is not the only pathogenic factor.
Correlation between GBS and infectious disease
A remarkable feature of GBS which distinguishes it from other neuropathies is its close
association with preceding infectious disease. An infection with the enteric pathogen
Campylobacter jejuni has most frequently been reported. Depending on the geographical area
where the studies were performed, 26 – 41% of GBS cases are preceded by a C. jejuni infection.
Cytomegalovirus infection is the second most common (5 – 15%) GBS-preceding event. Other
significantly associated infectious agents are Epstein-Barr virus, Mycoplasma pneumoniae, and
Hemophilus influenzae.
Hypotheses of autoimmune pathogenesis of inflammatory neuropathies
Some of the characteristics of inflammatory neuropathies point to an autoimmune pathogenesis. It
is thought that CIDP is a predominantly T cell mediated disease because high amounts of
infiltrating T cells can be found in nerve biopsies, effective therapy consists of T cell suppressive
drugs, soluble IL-2 receptor is found in serum, and high frequencies of T cells carrying a mutation
in the HPRT gene are found. GBS on the contrary is often considered to be mainly antibody
5mediated because of the anti-ganglioside antibodies that are present in the serum of GBS patients,
and because the earliest abnormality found in GBS-affected nerve is complement deposition2.
Traditionally, an autoimmune disease is regarded as T cell mediated or antibody or B cell
mediated, but this distinction is in most cases questionable, and totally overlooks the innate
immune system as possible pathogenic mediator. A strict attribution of T- versus B cell mediated
pathogenesis to CIDP and GBS is not plausible since autoantibodies can be found in CIDP
patients, and signs of T cell activation in GBS. In addition, for the production of antibodies of the
IgG1 and IgG3 isotype, like the anti ganglioside antibodies found in GBS, T cell help is needed.
Most likely, the innate immune system, the adaptive immune system including both B and T
lymphocytes, and regulatory systems are all involved in the development of autoimmune disease.
The molecular mimicry hypothesis has been thought out in most detail for the anti-ganglioside
antibodies in GBS patients. The concept is based on structural resemblance between a micro-
organism and the host. Glycosylations of the outer core of the lipo-oligosaccharide (LOS)
molecule of some C. jejuni strains resemble or are identical to glycosylations of the human
gangliosides, and antibodies that were raised against these epitopes on Campylobacter cross-react
with the corresponding eitopes on peripheral nerve gangliosides, thus leading to GBS. The
concept lead to the question whether there are bacterial strains that are more likely to lead to GBS
than others, the so called 'bad bugs'. This appears indeed to be the case. In Japan for example,
serostrain O:19 is more frequently found in GBS patients than in patients with uncomplicated
enteritis11. The same holds for serostrain O:41 in South Afrika12. However, other studies argue
against simple epitope differences as the basis of the development of GBS. It has been
demonstrated that although anti-ganglioside antibodies in Campylobacter-induced GBS are more
frequently found than in uncomplicated Campylobacter enteritis, the bacterial strains that are
isolated from both groups of patients are similar in their ganglioside-like epitopes on their LOS13.
A recent discovery may clarify this controversy: The high molecular weight LPS containing the
O-antigens-of Campylobacter is biochemically and genetically unrelated to LOS that in some
strains contains epitopes that resemble human gangliosides14;15. Furthermore, seroconversion of
C. jejuni strains has been reported 16. But besides the ganglioside-mimicking issue, it is
conceivable that other aspects of Campylobacter strains account for their GBS-inducing potential,
and that these factors are coincidentally linked to their serotype.
Although there is a strong correlation between GBS and certain preceding infectious diseases, it is
obvious that other factors play a role as well. Only two thirds of the GBS cases is preceded by an
infectious disease (though undetected infections can not be excluded), and not all patients
suffering from one of the infectious diseases that typically precedes GBS will develop GBS. It has
been estimated that only one in a thousand clinically overt Campylobacter infections leads to
6GBS. Genetic and non-genetic host factors have been put forward as risc factors for GBS.
Examples of genetic factors that have successfully been studied and are correlated with the
development of GBS are: Fc receptor polymorphisms17 and TNFα polymorphisms18, Of note,
HLA linkage has been studied but is absent or very weak19.
Immunological introduction
Immune responses against pathogens have extensively been described and can be classified
according to the part of the immune system that is involved or to the type of antigen against
which the reaction is directed. Both classifications are workable and will be used here.
An important division is between innate and adaptive immune systems. Adaptive immunity has
been studied more extensively than innate immunity, and comprises mainly T and B cell mediated
immunity that depends on rearrangment/recombination of antigen receptor gene segments in
combination with diversification and clonal selection. The adaptive immune system is able to
cope with rapidly changing pathogens. The innate immune system utilizes more preformed, germ-
line encoded receptors. This enables the innate immune system to react quicker than the adaptive
immune system, but only to conserved molecules of pathogens. Furthermore, the innate immune
system is able to recognize and eliminate cells that express 'danger' or 'stress' signals. Examples of
innate receptors are the LPS receptor CD14, Toll-like receptors, the mannose receptor, and NK
receptors and NKT cell receptors.
Because the molecular mimicry hypothesis put forward the importance of identical glycosylations
on pathogen and human ganglioside, the distinction between immunity against proteins and other
molecules may be of particular interest to GBS. A classical, adaptive immune response against a
protein of an extracellular pathogen comprises a MHC-restricted T cell response, T/B interaction,
and antibody production by the B cell, mainly of the IgG1 and IgG3 isotype. There are however
other scenarios possible. T-independent (TI) antigens that fulfill certain structural requirements
may lead to the production of antibodies of the IgM or IgG2 isotype. TI-2 antigens are mostly
molecules such as bacterial cell wall polysaccharides with highly repetitive structures20;21. There
are also non-MHC restricted T cells like γδ T cells and CD1 restricted αβ T cells. Especially the
recently described CD1b-restricted ganglioside-specific αβ T clones may play a role in the
development of GBS22, although the significance of this type of cells in vivo remains uncertain.
7γδ T lymphocytes
Because the γδ T cell will play an important role in Chapter 4 and 5, a specific introduction will
be given here. γδ T cells are generally considered as innate lymphocytes, and they make up a
minor population in human blood. Their TCR variability is not as high as found in αβ T cells, but
neither do they have a semi-invariant TCR like NKT cells. In blood, the expression of Vδ gene
segments is limited to Vδ2, and to a lesser extent, Vδ1. Subpopulations of γδ T cells expressing a
certain Vδ appear to have different distribution patterns and antigen specificity.
Circulating Vδ2 cells usually co-express the Vγ9 chain, and these Vδ2/Vγ9 cells expand in
numerous infectious diseases. They appear to react quicker than αβ T cells, produce γIFN23, and
have strong cytotoxic potential. Vδ2 cells recognize antigens in unprocessed form, and no known
antigen presenting molecule is needed. The antigens they recognize are phosphoantigens, which
are intermediates in the bacterial deoxyxylulose pathway, and alkylamine antigens24.
Aims of the study
The aims as described here reflect the questions that were raised before the project was started.
They were partially based on certain expectations, like for example the discovery of a T cell
stimulatory compound of myelin. As the project proceeded, unexpected results guided the
refinement of the aims, but the original form of the aims is presented below.
1) Describe the conditions for local T cell activation in peripheral nerve
2) Describe the direct reactivity of ex vivo T cells of GBS and CIDP patients against PNS myelin
3) Study cross-reactivity of T cells between Campylobacter and myelin constituents
4) Describe the T cell response of healthy donors and GBS patients against Campylobacter
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Expression of accessory molecules for T cell activation in peripheral
nerve of patients with CIDP and vasculitic neuropathy
Ildiko Van Rhijn,1 Leonard H. Van den Berg,1 Wendy M. J. Bosboom,1 Henny G. Otten2, and
Ton Logtenberg2
Departments of 1Neurology and 2Immunology, University Medical Center Utrecht, The
Netherlands
Published in Brain (2000), 123, 2020-2029
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Abstract
Vasculitic neuropathy and chronic inflammatory demyelinating polyneuropathy (CIDP) are
neuropathies characterized by a T lymphocyte infiltrate in the peripheral nerves. The
microenvironment in which these T cells become activated and the molecules and cells that play a
role in this process are incompletely understood. In immunohistochemical analysis, we studied
the presence of adhesion-, costimulatory-, and antigen presenting molecules on different cell
types as conditions for local T cell activation in human sural nerve biopsies of 7 CIDP and 3
vasculitic neuropathy patients and 3 healthy controls. In biopsies from CIDP and vasculitic
neuropathy patients, but not healthy controls, Schwann cells expressed the adhesion/T cell
stimulatory molecule CD58 (LFA-3). The CD58 molecule was also present on endothelial cells of
all vasculitic neuropathy patients and 1 CIDP patient. In biopsies from normal controls and
patients, CD54 (ICAM-1) expression was detectable on microvascular endothelial cells. In
addition, expression of the co-stimulatory molecule CD86 was detected on vascular tissue in
patients with vasculitic neuropathy. Although macrophages were always present in all subjects,
expression of the MHC-like molecule CD1a by macrophages was restricted to biopsies from 2
CIDP patients and 1 vasculitic neuropathy patient. Unexpectedly, Schwann cells of a single
vasculitis patient strongly expressed CD1b, a molecule involved in the presentation of self
glycolipids to T cells. Schwann cells in biopsies from patients and normal controls expressed high
levels of the invariant chain (CD74), a molecule involved in intracellular sorting of MHC class II
molecules. There was no evidence for the presence of dendritic cells in sural nerve biopsies.
These findings support a model in which T cell activation can be initiated and/or perpetuated
locally in sural nerve biopsies of patients with CIDP and vasculitic neuropathy and predict an
important role for Schwann cells and endothelial cells.
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) and vasculitic neuropathy are
peripheral nerve disorders of presumed autoimmune etiology. A role for T lymphocytes has been
suggested based on the observation that T cell infiltrates are present in biopsy specimens and
postmortem material of peripheral nerves1;25-28. Further support for T cell involvement in the
pathogenesis of CIDP comes from the notion that these patients have increased frequencies of
circulating activated and chronically stimulated peripheral T lymphocytes and elevated levels of
soluble interleukin-2 receptors4;5.
11
Although T lymphocytes are accepted to play a role in the development and/or perpetuation of the
inflammatory disease process, little is known about the processes and (auto)antigen(s) responsible
for the initiation and chronic course of these neuropathies29;30. Generally, T cell activation and
migration into peripheral tissues is a selective, multi-step process involving a myriad of molecules
expressed or induced on different cell types. The initial events leading to T cell activation are: 1)
adhesion and extravasation, 2) recognition of previously captured and processed antigen,
presented on MHC class I or II by a professional antigen presenting cell (APC) and 3) recognition
of costimulatory molecules like the classic examples CD80 (B7.1) and CD86 (B7.2) on the APC.
Subsequently the T cell will proliferate and differentiate into an effector cell. Normally these
events take place in the lymphnodes, but in autoimmune disease the immune response directed to
specific autoantigens may be initiated locally. Unlike in Guillain-Barré syndrome (GBS), in CIDP
or vasulitic neuropathy a link between preceding infections with micro-organisms and the
occurrence of disease has not been established. Thus, although a role for exogenous antigens
cannot be excluded, the initial immune response may also be induced by and directed against a
nerve-specific or vascular autoantigen. In that case the presence of molecules for adhesion,
antigen presentation and costimulation in peripheral nerve tissue is a prerequisite.
The anatomical site(s), cells and molecules that contribute to the autoimmune response resulting
in the development of CIDP or vasculitic neuropathy have not been well-established. Here, we
have performed an immunohistochemical analysis of cells and molecules involved in adhesion,
antigen presentation and T cell costimulation in sural nerve biopsies of patients with CIDP,
vasculitic neuropathy and, as a control, individuals without peripheral neuropathy. The results
support the concept that in the sural nerve microenviroment in CIDP and especially vasculitic
patients, presentation of autoantigen and local T cell stimulation may contribute to the initiation
and/or perpetuation of disease.
Materials and Methods
Patients
Nerve biopsies from 7 patients with CIDP and 3 patients with vasculitic polyneuropathy without
evidence for systemic vasculitis were included in the present study. The characteristics of the
patients and nerve biopsies are listed in Table 1. The CIDP biopsies widely varied in the number
of infiltrating T cells as we reported recently28. Patients 1-3 had increased numbers of T cells
compared with normal controls28. Patient 2 had received treatment with intravenous
immunoglobulin 2 months before the biopsy was taken. As normal controls, biopsy specimens
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were obtained from individuals that did not suffer from polyneuropathies and succumbed from
subarachnoidal bleeding or pulmonary embolism.
Immunohistochemical techniques
Serial transverse tissue sections of 6 µm were made on a cryostat and fixed in acetone. For
staining with the S100 antibody, acetone treatment was preceded by fixation with 4%
paraformaldehyde. The staining procedure for all antibodies (Table 2) was as follows: biopsies
were incubated overnight with the primary antibody diluted in PBS/1% BSA, supplemented with
5% horse or goat serum. Biopsies were rinsed with PBS and incubated for one hour with the
biotinylated secondary antibody (rabbit IgG/IgM or mouse IgG; Vector, Peterborough, England)
diluted 1:200 in PBS/1% BSA, followed by an one hour incubation with ABC peroxidase
(Vector). Color was developed with Nickel and Cobalt enhanced diaminobenzidine. The sections
were counterstained with Nuclear fast red, which also stains the myelin sheaths, before
dehydration and mounting. Black and white microphotographs were taken without filter resulting
in a grey counterstaining and a black diaminobenzidine staining in the pictures.
Optimal dilution for primary antibodies were first determined using tissue sections of human
tonsil and skin. These tissues also served as positive controls during each round of staining. In
negative control stainings, the same procedure was followed except that the primary antibody was
omitted.
In a first round of staining, sets of three serial sections were cut and the middle section was
stained with the CD3 monoclonal antibody to confirm the presence of infiltrating T lymphocytes.
The first and third section were used for staining with monoclonal antibodies specific for
Pat Age  Sex Biopsy M/S Course CSF EMG
y m prot  dy   % CD8+
CIDP
1 45 F 4 M>S Progr 340 D 111 37
2 49 F 5 M=S RR 350 D 87 59
3 29 F 5 M=S Progr 330 D 57 61
4 31 M 2 M>S RR 40 D 20 88
5 43 M 37 S>M Progr 50 D 16 54
6 45 M 14 M>S RR 80 D 14 15
7 29 M 168 M>S Progr 80 D 12 84
Vasculitis
1 64 M 5 M=S Progr 60 A 183 42
2 78 F 2 M=S Progr 30 A 161 30
3 58 F 8 M=S Progr nd A 75 41
   T cells
Table 1        Clinical data of patients with CIDP and vasculitic neuropathy
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adhesion (CD54, CD58), antigen presenting (HLA-DR, CD1a, CD1b, CD1c, CD1d), or
costimulatory (CD40, CD80, CD86) molecules. When positive staining of adhesion-,
costimulatory- or antigen presenting molecules was found, new sets of serial section were made
and stained with the positive monoclonal antibody alternating with monoclonal antibodies
specific for macrophages (CD68), Schwann cells (S100), endothelial cells (CD31) and B cells
(CD20). All biopsy specimens were analyzed for the presence of CD83 positive cells, as a marker
for the presence of dendritic cells. Table 2 lists the antibodies and dilutions used in the present
study.
Antigen Supplier Batch/clone Dilution Isotype
Adhesion 
CD31 (PECAM-1) Monosan EN-4 1:2500 IgG1
CD54 (ICAM-1) Becton/Dickinson LB2 1:200 IgG2b
CD58 (LFA-3) PeliCluster bric5 1:150 IgG2a
Antigen presenting 
HLA-DR Becton/Dickinson L1125 1:16000 IgG2a
CD1a Gift* Okt6 1:1000 IgG1
CD1b Gift* BCD1b3.1 1:1000 IgG1
CD1c Gift* F10/21A3 1:1000 IgG1
CD1d Gift* CD1d55 1:1000 IgG1
Co-stimulating 
CD40 Gift** BE-1 1:1000 IgG1
CD80 (B7-1) Pharmingen BB1 1:2000 IgM
CD80 (B7-1) Innogenetics 5B5 1:200 IgG3
CD80 (B7-1) Innogenetics B7.24 1:200 IgG2a
CD86 (B7-2) Pharmingen 2331 (fun-1) 1:500 IgG1
Other
CD3 (pan-T cells) Dako 035 (202) 1:200 Rabbit polycl.
CD20 (B cells) Dako L26/91 1:600 IgG2a
CD68 (Macrophages) Dako KP/1 047(101) 1:1000 IgG1
CD83 (Dendritic cells) Immunotech HB15a/lot01 1:50 IgG2b
S100 (Schwann cells) Sigma SH-B1 1:60000 IgG1
Table 2 Antibodies used against different molecules
**CD40 was kindly provided by Dr. T.W. LeBien, Minneapolis
*CD1 antibodies were kindly provided by Dr. S.A. Porcelli, Boston
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Results
Immunohistochemical procedures and dilutions of antibodies were validated by staining tissue
sections of human skin and tonsil. Using the dilutions listed in Table 2, all antibodies showed
specific staining with anticipated distribution patterns of positive cells in human skin sections
(anti CD1a) or human tonsil sections (all other antibodies)31-33. No detectable background staining
was observed using these conditions. Staining of skin sections with the CD1a-specific monoclonal
antibody showed the presence of CD1a+ Langerhans cells. In tonsil sections, CD40 positive
clusters of B lymphocytes, CD80 and CD1d positive germinal center B cells, and CD86, CD83,
and CD1b positive interdigitating reticulum dendritic cells were clearly identified (not shown).
Table 3 and Figures 1-6 show the results of the immunohistochemical staining of peripheral nerve
biopsies.with antibodies specific for molecules involved in adhesion, antigen presentation or
costimulation.
Antigen Supplier Batch/clone Dilution Isotype
Adhesion 
CD31 (PECAM-1) Monosan EN-4 1:2500 IgG1
CD54 (ICAM-1) Becton/Dickinson LB2 1:200 IgG2b
CD58 (LFA-3) PeliCluster bric5 1:150 IgG2a
Antigen presenting 
HLA-DR Becton/Dickinson L1125 1:16000 IgG2a
CD1a Gift* Okt6 1:1000 IgG1
CD1b Gift* BCD1b3.1 1:1000 IgG1
CD1c Gift* F10/21A3 1:1000 IgG1
CD1d Gift* CD1d55 1:1000 IgG1
Co-stimulating 
CD40 Gift** BE-1 1:1000 IgG1
CD80 (B7-1) Pharmingen BB1 1:2000 IgM
CD80 (B7-1) Innogenetics 5B5 1:200 IgG3
CD80 (B7-1) Innogenetics B7.24 1:200 IgG2a
CD86 (B7-2) Pharmingen 2331 (fun-1) 1:500 IgG1
Other
CD3 (pan-T cells) Dako 035 (202) 1:200 Rabbit polycl.
CD20 (B cells) Dako L26/91 1:600 IgG2a
CD68 (Macrophages) Dako KP/1 047(101) 1:1000 IgG1
CD83 (Dendritic cells) Immunotech HB15a/lot01 1:50 IgG2b
S100 (Schwann cells) Sigma SH-B1 1:60000 IgG1
Table 2                      Antibodies used against different molecules
*CD1 antibodies were kindly provided by Dr. S.A. Porcelli, Boston
**CD40 was kindly provided by Dr. T.W. LeBien, Minneapolis
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Pat CD54 CD58  HLA-DR CD1a CD1b CD1c CD1d CD40 CD80 CD83 CD86
1 + (e) + (s) + (s, e, m, p) - - - - - - - -
2 + (e) + (s, e) + (s, e, m) - - + (b) - - - - -
3 + (e) - + (s, e, m) - - + (b) - - - - -
4 + (e) + (s) + (s, e, m) - - + (b) - - - - -
5 + (e) - + (s, e, m) + (m) - - - - - - -
6 + (e) + (s) + (s, e, m, p) + (m, p) - - - - - - -
7 + (e) + (s) + (s, e, m, p) - - + (b) - - - - -
1 + (e) + (s, e) + (s, e, m) - - + (b) - - - - -
2 + (e) + (s, e) + (s, e, m) + (m, s) + (s) + (b) - - - - + (e)
3 + (e) + (s, e) + (s, e, m, p) - - - - - - - + (e)
1 + (e) - + (s, e, m) - - - - - - - -
2 + (e) - + (s, e, m) - - - - - - - -
3 + (e) - + (e, m) - - - - - - - -
CIDP
Vasculitis
Normal
Table 3  Results of the immunohistochemical analysis on sural nerve biopsies of patients 
and controls
Pat = patients, + = positive staining, - = no staining. Localisation of positive staining: e = endothelial cells, s = 
Schwann cells, m = macrophages, p = perineurial cells, b = B cells
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Expression of adhesion molecules in sural nerve biopsies
Serial sections of sural nerve biopsies were stained with the monoclonal antibodies specific for
CD54 and CD31. CD31 (platelet/endothelial cell adhesion molecule 1, PECAM-1) is known to be
expressed on all continuous endothelia; CD54 (intercellular adhesion molecule 1, ICAM-1) is
typically expressed at high levels on activated endothelial cells. Representative results are shown
in Figure 1. As expected, endothelial cells lining the epineurial and endoneurial blood vessels
stained positive for the CD31 molecule in normal controls and in patients with CIDP and
vasculitic polyneuropathy (Fig. 1a). In the sural nerve biopsies of all normal controls and patients
with polyneuropathy analyzed, CD54 expression was found on the endothelial cells lining
endoneurial vessels, whereas no staining of epineurial arterioles was observed (Fig. 1b). No other
cell types in the biopsy specimens expressed the CD54 molecule.
The adhesion molecule CD58 (lymphocyte function-associated molecule 3, LFA-3), is known to
be expressed on the surface of epithelial and endothelial cells and erythrocytes. We observed
expression of CD58 by myelinating (Nuclear fast red-positive) and non-myelinating (Nuclear fast
red-negative) Schwann cells in sural nerve biopsies of all 3 vasculitic neuropathy patients and 5
CIDP patients (Fig. 2a). In all 3 vasculitic neuropathy patients but only in 1 out of 5 CIDP
patients, CD58 was also present on endothelial cells in both the epineurium and endoneurium
(Fig. 2e). In contrast, no CD58 staining was observed in the sural nerve biopsies of normal
controls (Fig. 2d).
Staining with an antibody specific for CD68, a widely used marker for cells of the
macrophage/monocyte lineage and of dendritic cells, unveiled the presence of CD68+ cells in the
endoneurium and epineurium. The CD68+ cells did not co-localise with the CD58+ Schwann
cells (Fig. 2b).
Figure 1
Serial sections of a nerve biopsy
from CIDP patient C6. Endothelial
cells, stained with the EN-4
antibody, (a) are positive for CD54
(b). Note that some epineurial
arterioles do not stain whereas all
endoneurial vessels are positive.
Bars: 50µm.
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Expression of antigen presenting molecules
HLA-DR expression was observed on CD31+ endothelial cells and on CD68+ cells in both
epineurium and endoneurium in biopsy specimens of all patients and normal controls. In most
patients and normal controls, we observed HLA-DR expression by non-myelinating Schwann
cells, identified by expression of the S100, an intracellular Ca-binding protein, and the absence of
myelin (Nuclear fast red staining). Myelinating Schwann cells were always HLA-DR-negative.
Some perineurial cells of unknown lineage were also HLA-DR+. Representative results are
shown in Figure 3.
Antigen presenting capacity has recently been ascribed to members of the CD1 gene family34. In
addition, CD1a, b, and c are markers for subsets of dendritic cells35;36. In one out of three patients
with vasculitic neuropathy and two out of seven CIDP patients, weak CD1a expression was
associated with macrophages (not shown). No CD1a staining was observed in sural nerve biopsies
of normal controls. In a single vasculitic neuropathy patient, Schwann cells weakly expressed
Figure 2
Figure a and b represent serial sections of a nerve biopsy from CIDP patient C6. The anti CD58 monoclonal
antibody stains Schwann cells (a). Positivity is not associated with surrounding macrophages, as shown by the
localization of CD68+ cells (b). The square in a is enlarged in c. CD58 positivity is associated with the rim of
myelin sheats, probably Schwann cell plasmalemma, and non-myelinating Schwann cells (arrows). A section
of a nerve biopsy from a normal control is negative for CD58 (d). Serial sections from biopsy specimens of
vasculitic neuropathy patient V3 stained with anti CD58 (e) and anti CD31 (f) monoclonal antibodies shows
that endoneurial vessels are CD58+. Bars: 50µm.
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CD1a (not shown) and strongly expressed CD1b (Fig 4a). In two vasculitic neuropathy patients
and 4 CIDP patients, CD1c expression was observed in cells with a perivascular localization (Fig
4b). Staining of serial sections with a CD20 antibody confirmed that these CD1c+ cells belong to
the B lymphocyte lineage (Fig. 4c) No CD1d expression was detected (not shown).
Finally, CD83 expression was not detectable in any of the nerve biopsy specimens studied.
Figure 3
Serial sections of a nerve
biopsy from CIDP patient C4
stained for the Schwann cell
marker S100 (a), HLA-DR (b),
CD31, a marker for endothelial
cells (c) and macrophage
marker CD68 (d). HLA-DR
positivity (b) is not associated
with the presence of
macrophages (d) or vascular
tissue (c), but likely associated
with non-myelinating Schwann
cells. Bars: 50µm.
Figure 4
Section of a nerve biosy from vasculitis patient V2 demonstrate myelinating Schwann cells expressing high
levels of CD1b (a). Perivascular localization and colocalization of CD1c (b) and the B cell marker CD20 (c) in
serial sections of vasculitic neuropathy patient V1. Bars: 50µm.
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Expression of costimulatory molecules
Expression of the costimulatory molecule CD40 was not detectable in biopsy specimens from
patients or normal controls. CD80 (B7.1) and CD86 (B7.2) are costimulatory molecules expressed
on activated B cells, macrophages and dendritic cells. The CD80-specific IgM monoclonal
antibody BB1 from Pharmingen (San Diego, CA, USA) brightly stained both myelinating and
non-myelinating Schwann cells in all biopsy specimens (Fig. 5a), whereas a complete absence of
staining was observed with two IgG monoclonal antibodies specific for CD80 (Innogenetics,
Ghent, Belgium), even in T cell rich areas (Fig. 5b and 5c). It was recently shown that the BB1
monoclonal antibody recognizes both CD80 and the cell surface form of the invariant chain
(CD74)37. We conclude that the Schwann cells do not express CD80 yet express high levels of
CD74, a molecule that associates with MHC class II molecules to prevent peptide binding. We
were unable to confirm CD74 expression with anti-CD74 monoclonal antibodies because of the
unacceptably high background in immunohistochemical analysis. Note that other MHC class II-
positive cells like endothelial cells and perineurial cells did not stain with the Pharmingen anti
CD80/CD74 antibody.
Weakly CD86-positive endothelial cells were detected in 2 vasculitic neuropathy patients but not
in the other biopsy specimens, despite the presence of CD3+ T lymphocytes (Fig. 6a-c).
Figure 5
Nerve biopsy section of CIDP patient C5 stained with the Pharmingen anti CD80 antibody (a). Serial sections
of the nerve biopsy of patient C3 demonstrate the presence of T cells using anti CD3 antibodies (Fig 6b) and
the absence of CD80 using the anti CD80 (Innogenetics, 5B5) monoclonal antibodies. Bars: 50µm.
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Discussion
We have studied the expression of adhesion-, antigen presenting-, and costimulatory molecules by
cells present in peripheral nerves of normal controls and patients with CIDP and vasculitic
polyneuropathy. These molecules are involved in homing, priming and expansion of T
lymphocytes and the analysis of their expression patterns in normal and disease-associated
peripheral nerve tissue may contribute to the understanding of the pathogenesis of inflammatory
peripheral neuropathies. Although in our study only the sural nerve was investigated and the
disease process may well involve various other and more proximal nerves, the sural nerves in all
vasculitic neuropathy patients and 3 of the 7 CIDP patients showed increased numbers of T cells
compared with normal and non-inflammatory disease controls as was measured in a previous
study28.
One of the most salient findings of the current study is that the CD58 (LFA-3) molecule was
found on myelinating and non-myelinating Schwann cells in sural nerve biopsies of all 3
vasculitic neuropathy patients and 5 CIDP patients. In striking contrast, no CD58 staining was
observed in the sural nerve biopsies of normal controls. The CD58 molecule, a member of the Ig
superfamily, is expressed on both hematopoietic and non-hematopoietic cell types. CD58
functions as an adhesion molecule and mediates signal transduction through its counter-receptor
CD2 expressed on natural killer cells and T lymphocytes. Signaling via CD58/CD2 induces IL-12
responsiveness of activated T cells during their maturation into effector cells, resulting in T cell
proliferation, development of cytotoxic potential and production of -IFN38. In model systems, it
has been shown that increased levels of CD58 expression correlates with increased production of
the cytokines -IFN, IL2 and TNF by effector T lymphocytes and may increase susceptibility
Figure 6
Vasculitis patient V2 (a) stained for CD86. Positivity is mainly localized on endoneurial vessels, as shown by the
adjacent section stained with anti CD31 (b). Normal control N3 stained for CD86 (c) illustrates the absence of
CD86 positivity as seen in most other specimens. Bars: 50µm.
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of CD58+ target cells to lysis39. Neonatal rat Schwann cells exert immune functions in vitro and,
based on their ability to produce complement regulatory proteins and cytokines in vivo, human
Schwann cells have been postulated to possess the capacity to present antigen to autoreactive T
cells in inflammatory neuropathies40;41. CD58 expressed by Schwann cells in both CIDP and
vasculitic material, but not in normal controls is in line with these findings and suggest that
Schwann cells may function as an alternative accessory cell for T cell activation and/or constitute
a target for lysis by activated cytotoxic T cells.
CD58 expression was also found on endothelial cells in sural nerve biopsy specimens in all three
vasculitic neuropathy patients, one out of six patients with CIDP but not in sural nerve biopsies of
normal controls. Endothelial cells have been shown to stimulate T lymphocytes in vitro, resulting
in the induction of proliferation, cytokine production or development of cytotoxic potential42-45. A
number of studies has shown that stimulation of T lymphocytes is dependent on expression of
CD58 by endothelial cells and independent of the expression of CD80 or CD86 co-stimulatory
molecules42-44;46. In the current study, the co-stimulatory molecule CD86 was found on
endothelial cells in two patients with vasculitic neuropathy but not in CIDP patients or normal
controls, whereas we did not observe expression of CD80. In vitro cultured and presumably
activated microvascular endothelial cells express CD86 that acts as a co-stimulatory molecule for
T cell activation47;48. Collectively, our experiments suggest that CD58+ and/or CD86+ sural nerve
endothelial cells may play a role in the local activation of T lymphocytes in CIDP and vasculitic
neuropathy. Of note, the observation that the endothelial cells of all three vasculitic neuropathy
patients and only one of six CIDP patients expressed CD58 and that CD86 expression was
entirely restricted to endothelial cells of patients with vasculitic neuropathy suggests that
endothelial cells may play a more prominent role in local T cell activation in vasculitic
neuropathy than in CIDP.
We observed that endoneurial but not epineurial blood vessels in normal controls and patients
constitutively express the CD54 (ICAM-1) adhesion molecule. CD54 is constitutively expressed
on endothelial cells in some tissues and contributes to T cell activation and migration across the
endothelium49. A role for CD54 in immune-mediated disorders of the nervous system is suggested
by its immunohistochemical localization in the lesions of experimental allergic encephalomyelitis
and in multiple sclerosis plaques50-52. In the peripheral nervous system, upregulation of CD54 on
endoneurial macrophages and endothelial cells in Lewis rat experimental autoimmune neuritis
(EAN) was found and the administration of a monoclonal antibody to CD54 abrogated disease in
EAN53;54. However, increased concentrations of the soluble form of this molecule were detected
in serum or CSF from patients with multiple sclerosis but not in GBS55;56. In vasculitic
neuropathy and CIDP, the role of the CD54 adhesion molecule remains uncertain as T cells are
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located predominantly in the epineurium in these diseases28, and ICAM-1 expression is
predominantly in the endoneurium and does not seem to be upregulated in disease biopsies
compared with normal controls. This is in contrast with the endothelial leukocyte adhesion
molecule (ELAM-1) which was shown to be expressed in epineurial, not endoneurial, endothelial
cells in sural nerve biopsies of 5 out of 10 CIDP patients and 1 out of 5 vasculitis patients, but not
in the controls57. It is possible that the adhesion molecules which are involved in the extravasation
of infiltrating cells are different in epineurial or endoneurial endothelial cells.
Dendritic cells are professional antigen presenting cells involved in the initiation of T cell-
dependent immune responses. They have been implicated in a number of human autoimmune
diseases as well as in animal autoimmune models35;58-60. Using MHC class II, CD1, CD40, CD54,
CD68, CD80, CD86, and CD83-specific antibodies, we found no evidence for the presence of
dendritic cells in sural nerve biopsies, which is in contrast to other chronic autoimmune
conditions such as rheumatoid arthritis and psoriasis61.
Our observation that Schwann cells strongly reacted with the BB-1 antibody but lacked reactivity
with two other anti CD80 antibodies, in combination with the recent finding that BB-1 cross-
reacts with an epitope on the CD74 molecule led us to conclude that Schwann cells express high
levels of CD74. We could not directly confirm this observation by immunohistochemical analysis
with an anti CD74 antibody because of an unacceptably high background staining in nerve tissue.
BB-1 staining did not unveil obvious differences between myelinating or non-myelinating
Schwann cells or between normal and diseased tissues. In contrast, non-myelinating but not
myelinating Schwann cells expressed MHC class II molecules. CD74 functions to prevent peptide
binding to MHC class II, facilitates MHC class II transport and enhances its localization to
antigen-processing compartments62. CD74 is produced in molar excess of MHC class II and some
is expressed at the cell surface independent of or in association with MHC class II molecules63.
CD74 has been reported to act as a co-stimulatory molecule via binding of CD44 to chondroitin
sulphate linked to CD7464. A putative role for CD74 in antigen presentation and/or co-stimulation
by Schwann cells remains to be established. Previous studies on MHC class II expression by
Schwann cells are not consistent. Initially, class II expression was reported on both myelinating
and non-myelinating Schwann cells 65. Others found no class II expression66, or a distribution
pattern similar to our results67. These differences may reflect immunohistochemical techniques or
antibodies used.
CD1a and b have recently been reported to be expressed on macrophages and myelinated nerve
fibres in sural biopsies of patients with inflammatory neuropathies68. Our results with regard to
CD1a and CD1b were similar: Weak CD1a expression on macrophages was observed in 2 CIDP
patients and one vasculitic neuropathy patient, and CD1a and CD1b expression on Schwann cells
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was observed in one patient with vasculitic neuropathy. Stainings with anti CD1c and anti CD20
revealed that the expression of CD1c was restricted to B cells, and not found in normal controls.
Our CD1d antibody clearly showed that there was no CD1d expression in diseased or normal
peripheral nerve. We unexpectedly found weak CD1a and strong CD1b expression by Schwann
cells in a single patient with vasculitic neuropathy. These MHC-like molecules are commonly
expressed by professional antigen presenting cells and have hitherto not been associated with
Schwann cells. In patients with multiple sclerosis, increased numbers of CD1b-restricted T cells
that are specific for self-glycolipids are found in the peripheral blood69. Collectively, these
findings suggest that CD1b+ Schwann cells may be capable of presenting self glycolipids to
autoreactive T lymphocytes.
The results of the present study support a model in which T cell activation can be initiated and/or
perpetuated locally in sural nerve biopsies of patients with CIDP and vasculitic neuropathy and
predict an important role for Schwann cells and endothelial cells.
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Abstract
In the inflammatory peripheral neuropathies chronic inflammatory demyelinating polyneuropathy
(CIDP) and Guillain-Barré syndrome (GBS), immune recognition of peripheral nerve myelin has
been suspected as the basis for autoimmune destruction. To unveil the identity of T cell
stimulatory antigens and to gain insight in the nature of the response, we prepared a panel of
peripheral nervous system (PNS) myelin antigens suitable for T cell stimulations. Peripheral
blood mononuclear cells (PBMC) of eight CIDP, three GBS patients, and eleven controls were
stimulated directly, or with autologous dendritic cells (DC) as antigen presenting cells (APC),
with different PNS myelin preparations. Also, T cell lines reactive to Campylobacter jejuni, a
pathogen associated with GBS, were generated and tested for cross reactivity with myelin
preparations. Although a strong memory T cell response against a standard recall antigen was
always present, no response against any of the antigen preparations of PNS myelin could be
demonstrated. In addition, we did not find evidence for cross-reactivity of Campylobacter jejuni-
reactive T cells with PNS myelin antigens.
Introduction
Peripheral nervous system (PNS) myelin is most likely the target of immune attack in
inflammatory neuropathies like chronic inflammatory demyelinating polyneuropathy (CIDP) and
Guillain-Barré syndrome (GBS). Both diseases are characterized by weakness and sensory
deficits, though GBS has an acute onset and monophasic course and CIDP is a chronic or
relapsing-remitting disease. Most GBS cases are triggered by a preceding infectious disease, most
often a Campylobacter jejuni enteritis70-72. Immune attack of myelin in CIDP and GBS is
suggested by histological and electrophysiological evidence for demyelination and the presence of
antibodies against constituents of myelin. Among these, antibodies against P073, P210, PMP2274,
and gangliosides GM1 and GQ1b have been identified13.
The involvement of T cells in the pathogenesis of CIDP and GBS is suggested by several
observations. Patients have a high titre of sIL2R in serum or CSF9, a T cell infiltrate is present in
affected peripheral nerves1, and a high frequency of HPRT-mutated T cells can be found in
patients4. In general, work on T cell reactivity is hampered by technical incoveniences like the
preparation of antigen suitable for T cell culture, the inevitability of working with living cells, and
the lack of standardized, satisfactory methods and protocols. In the field of T cell research,
working with clones is common practice because of the advantages of high reproduceability and
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the possibility to perform multiple experiments with the same cells. However, it is questionable
whether clones still reflect the in vivo situation after a long period of in vitro culture and
manipulation. Clones are usually produced on a priory selected antigens, and the mere fact that a
clone reacting to a certain self-antigen exists does not mean that the antigen is relevant during
disease, nor that the clone is potentially pathogenic. This is supported by the fact that clones or
cell lines against self antigens can often be isolated from healthy donors as well as patients
suffering from autoimmune disease. Because of these drawbacks of working with clones, we
chose to perform our experiments with freshly isolated PBMC.
For practical reasons, antigens selected for T cell stimulations are often proteins that are major
constituents of myelin. Minor protein constituents, as well as non-protein antigens, are easily
overlooked as potential auto-antigens, but have been shown to be able to trigger responses,
despite their low abundancy75. Recently, T cells have been described that react to a variety of
non-protein antigens like self and non-self glycolipids76;77, isoprenoid derivatives78, and
alkylamine antigens24. Lipids are a major part of myelin and may as well play a role in
autoimmunity. Therefore we prepared lipid extracts in addition to a complete set of proteins with
a broad range of hydrophobicity from normal PNS myelin. We also used a crude preparation of
CIDP-affected nerve material. These different antigen preparations were used to stimulate ex vivo
PBMC of GBS and CIDP patients and healthy controls. In addition, we generated
Campylobacter-reactive polyclonal cell lines and studied the cross-reactivity of these cell lines
with myelin preparations.
Material and methods
Patients and controls
For experiments with PBMC, eight CIDP patients with different levels of disease activity and
three GBS patients in the acute phase of disease were used. An overview of the clinical status of
the patients that were included in this study is given in Table 1. We intentionally included patients
that were recovered or in remission because we anticipated differences in stimulatory capacities
between acitvated T cells and resting memory T cells. PBMC from healthy blood bank donors
were used as controls.
Normal control PNS myelin was obtained from obductions from individuals that did not suffer
from polyneuropathies and succumbed from subarachnoidal bleeding or pulmonary embolism.
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Antigen preparation
PNS myelin was fractionated as
described for CNS myelin79. In short,
cauda equina was homogenized in
0.29 M sucrose solution, layered over
a 0.80 M sucrose solution and after
centrifugation, the interface was
washed in distilled water, pelleted
and freeze dried. This preparation
was called 'sucrose myelin'. For
delipidation, myelin was dissolved in
2:1 chloroform methanol containing
1% TFA and precipitated in four
volumes of ether which was repeated
four times. After the last
precipitation, delipidated myelin was dissolved in 2 chloroethanol containing 0.1% TFA, and
mixed with three volumes of distilled water. This suspension was filtered and loaded on a C3
HPLC column. Fractions were eluted in solvent A (water with 0.1% TFA) with an increasing
percentage of sovent B (80% THF, 20 % acetonitrile, 0.1% TFA), or with solvent B only. These
preparations were called 'HPLC fractions' and 'HPLC myelin' respectively. Eluted material was
freeze dried, dissolved in 2-chloroethanol, and stored at –20°C. Prior to use in a T cell
stimulation, a small amount of the fractions was dialyzed in an eppendorf tube against water with
a 3.5 kDa cut-off regenerated cellulose membrane (Spectrum Medical Industries, Laguna Hills,
CA). The protein concentration of the dialyzed preparations was assessed by the DC Protein
Assay (Bio-Rad, Hercules, CA).
To assess the resolution of the HPLC run, fractions were analyzed by SDS-PAGE on 12%
polyacrylamide gels using the mini protean II system of Bio-Rad. One hour electroblotting on
nitrocellulose membrane (Bio-Rad) was carried out using the mini transblot system (Bio-Rad).
Fixed proportions of each fraction, 15 µg on average, was run per lane. Gels were stained with
Coomassie Brilliant blue for protein detection Blots were incubated with anti-MBP clone B103.1
(Biogenensis, Poole, UK), anti-αB crystallin clone JAM07, or anti-P0 clone D4IE4 (kindly
provided by Dr. B. Erne, Basel, Switzerland) in PBS/1%BSA, followed by biotinylated horse
anti-mouse secondary antibody (Vector, Peterborough, England) diluted 1:200 in PBS/1% BSA,
Patient Sex Age Duration disease Infection
(years) (months)
CIDP
C1 F 42 3 -
C2 F 49 8 -
C3 M 35 5 -
C4 M 45 4
a,b
-
C5 M 48 4
a
-
C6 M 60 14 -
C7 M 55 11 -
C8 M 32 9 -
GBS (days)
G9 M 64 10
a
C. jejuni
G10 F 49 5 C. jejuni
G11 M 35 23 -
a
PBMC of these patients were also tested 6 months later
b
This patient received  IVIg therapy between two experiments.
Table 1     Patient data
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followed by an one hour incubation with ABC peroxidase (Vector). Color was developed with
Nickel and Cobalt enhanced diaminobenzidine.
Folch extraction of lipids was performed on 500 mg freeze-dried 'sucrose myelin'. The myelin
was sonicated in 2.7 ml distilled water, and 9 ml 2:1 chloroform methanol was added. After
vortexing and centrifugation, both the upper and lower phase were preserved. A small amount of
each extract was dried and weighed to determine the contents of recovered material. Prior to use
in T cell stimulations, a small amount of the fractions was dried under a stream of nitrogen, and
sonicated into culture medium.
It has been suggested that abnormalities in the myelin itself like mutations in certain proteins, or
infections, or aberrant expression of certain proteins, may lead to immune activation and
autoimmunity80;81. In order to study whether CIDP-derived nerve material is more immunogenic
than control material, we tested CIDP-derived material of two patients. Because we could obtain
only small amounts of tussue, no purifications were performed on this material. Sural nerve
biopsies are in some cases taken for diagnostic purposes from patients with CIDP. During the
process of freezing this material for immunohistochemical analysis, the ends of the biopsy are
usually discarded. We collected the ends of two CIDP biopsies (of patients C2 and C6),
homogenized the tissue, followed by sonication.
Campylobacter jejuni strain D, an isolate of a GBS patient82 with GM1-like epitopes was used.
Bacteria were cultured at 37°C on 5% lysed horse blood-Columbia agar under microaerophilic
conditions (5% O2, 10% CO2 and 85% N2 ).
Bacteria from overnight cultures were washed in PBS, suspended in H2O, heated for 10 minutes
at 100°C, and sonicated.
T cell cultures and proliferation assays
Heparinized blood from a CIDP or GBS patient and from a healthy control subject was collected
on the same day and processed in parallel. Blood was diluted 1:1 in PBS and centrifuged over
Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) at 900 g during 20 minutes. After two
washes in PBS, the cells were counted and resuspended at 106 cells/ml in culture medium. Culture
medium consisted of RPMI 1640 (Life Technologies, Paisley, Scotland) with L-glutamine, 100
U/ml penicillin, 100 U/ml streptomycin and 5% heat inactivated human pooled serum. For direct
proliferation assays, 100 µl aliquot of the PBMC and 100 µl culture medium with antigen or at
double the final concentration were mixed in roundbottom 96-wells microtiter plates and cultured.
1 µCi of 3H labeled thymidine was added to triplicate wells at day 5 of culture. After 18 hours
cells were harvested onto filter papers and counted in a -counter. Stimulation index was defined
as (3H thymidine incorporation with antigen) / (3H thymidine incorporation without antigen).
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In some experiments we used cultured autologous dendritic cells (DC) as antigen presenting cells
(APC). These cells have been shown to possess strong antigen presenting and costimulatory
capacities83;84. Crosspresentation of external protein antigens on MHC class I molecules has been
reported85;86, and antigen presentation on CD1 isoforms87. PBMC were allowed to adhere to tissue
culture flasks during 2.5 hours. The non-adherent cells were frozen and the adherent cells were
cultured for 3 to 5 days in medium containing 1000 U/ml IL-4 (Strathmann Biotech Hannover,
Germany) and 50 ng/ml GMCSF (Schering-Plough, Kenilworth, NJ). In some cases these DC
were cultured for an additional two days in medium containing 2.5 ng/ml TNF-α (Intergen,
Oxford, UK), 0.5 µg/ml IL-1β (Srathmann Biotech), 1 µg/mlin PGE2 (Sigma, St. Louis, MO), and
1000 U/ml IL-6 (Roche Diagnostics, Basel, Switzerland) in addition. DC were irradiated (2500
rad) and washed in culture medium before use. The non-adherent cells were thawed and used as
responder cells in a 3H thymidine incorporation assay.
Polyclonal C. jejuni-reactive T cell lines were generated by stimulation of PBMC of two different
healthy donors with Campylobacter sonicate in culture medium without cytokines. After 17 days,
a second round of stimulation was performed in the presence of 10 ng/ml IL-15 (PeproTech
Rocky Hill, NJ), in the presence of autologous irradiated PBMC as APC. The reactivity of the
cells was tested with APC and without cytokines at 17 days after restimulation.
Tetanus toxoid (TT) (SVM, Bilthoven, The Netherlands) was used at 10 µg/ml.
Toxicity of myelin preparations was tested by adding the highest concentration myelin to a TT
stimulation. The amount of 3H thymidine incorporation of the TT stimulation with or without
myelin was compared.
Results
A chromatogram of a HPLC run is shown in Figure 1. In order to get an idea of the resolution of
the fractionation, and of the contents of the fractions, we ran SDS-PAGE on the fractions,
followed by western blotting. The presence of MBP, αB crystallin, and P0 in the fractions was
monitored because they represent a hydrophilic, a rare, and a hydrophobic protein respectively.
Figure 1 shows the distribution of these proteins, relative to the chromatogram.
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A total of 8 CIDP patients, 3 GBS patients, and 11 healthy blood donors was tested for anti-
myelin T cell reactivity. Upon direct in vitro stimulation of PBMC, all subjects reacted to
stimulation with TT with stimulation indices ranging from 13 - 25, but none of the subjectes
showed a stimulation index higher than 3.8 to any of the myelin preparations. Eight subjects were
also tested with autologous DC as APC. TT-specific proliferation indices were higher than
without DC (up to 79), but no higher myelin-specific stimulation indices were obtained using DC.
Many authors consider a stimulation index >2 as significant. Therefore, we looked at all myelin
preparations that elicited a stimulation index >2 in our experiments. In the group of controls we
observed 11 stimulation indices >2, spread over 9 different myelin preparations, and in the group
of patients we observed 12 stimulation indices of >2, spread over 11 different myelin
preparations.
Figure 1
RP-HPLC chromatogram of sucrose gradient purified, delipidated PNS myelin. Myelin was applied to a C3
column and eluted with an increasing percentage of sovent B (80% THF, 20 % acetonitrile). The 36 fractions that
were collected were analyzed by SDS-PAGE followed by immunoblotting. The bars show the projections of
immunoreactivity on the chromatogram.
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An example of a direct PBMC stimulation and a stimulation with DC are given in Figure 2.
Toxicity of 'HPLC myelin' was tested by adding the highest concentration tested to a TT
stimulation. We never noticed a substantial decrease of the TT response.
Campylobacter-specific cell lines were sucessfully created from PBMC from three out of three
different healthy blood bank donors. The reactivity to Campylobacter, sucrose myelin, and upper
and lower phase of a Folch extraction of PNS myelin are shown in Figure 3. The Campylobacter-
specific cell lines were reactive to Campylobacter, but not to the myelin preparations tested.
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Figure 2
Reactivity of two different
CIDP patients to PNS
myelin antigens. Freshly
isolated PBMC (left graph)
or DC that were generated
with GMCSF and IL-4 and
responder cells in a 1:20
ratio (right graph) were
stimulated with 1, 10, or 100
µg/ml total HPLC myelin,
or 10 µg/ml of the HPLC
fractions or the Folch
extracts.
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Discussion
In order to test T cell reactivity of patients with inflammatory neuropathy against suspected auto-
antigens, PNS myelin lipids and proteins were isolated. Proteins were fractionated by HPLC, and
since we successfully eluted MBP, αB crystallin, and P0 from the column, we expect that all
proteins with intermediate hydrophobicity were also eluted. None of the antigenic preparations
was toxic for T cells. Using these preparations for T cell stimulations we could only measure very
low and inconsistent proliferative responses.
A conclusion that a certain phenomenon does not exist, should be supported by strong indications
that the experimental set up was actually suitable to measure the phenomenon at all. In all our
experiments, TT was taken along as a model recall antigen. Since most people are vaccinated
against tetanus, this antigen is used by many researchers as a standard control for the presence of
a functional memory response in the CD4+ T cell compartment. Comparing the observed
vigorous responses to TT to the low responses to myelin, we conclude that a conventional CD4+
memory T cell response against peripheral myelin components does not exist in CIDP and GBS
patients. We were also unable to detect low but consistent responses against any of the peripheral
myelin components we isolated. Instead, we detected low responses against different myelin
antigen preparations, both in patients and healthy controls. This means that there is no universal
immunodominant antigen present in PNS myelin that was hitherto not recognized as such.
Addition of DC to cultures of PBMC increased the proliferative response to TT, but higher
myelin-specific stimulation indices could not be measured. Proper controls for cross-presentation
by DC in our experiments were not available. Therefore we can not conclude that MHC Class I
antigen presented myelin antigens do not play a role in CIDP and GBS.
Polyclonal Campylobacter-reactive T cell lines that could be effectively restimulated in vitro with
Campylobacter, did not react to any of the PNS myelin preparations. This indicates that T cell
Figure 3
PBMC of three different
healthy blood bank donors
were used to generate C.
jejuni-specific cell lines.
After two stimulations with
crude C. jejuni sonicate, the
reactivity of the cell lines
was tested with autologous
irradiated PBMC as APC.
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stimulatory components of crude preparations of Campylobacter are not present in PNS myelin
preparations. Although technical limitations of the assays used can not be excluded, these data
suggest that a T cell stimulatory cross-reactive compound in PNS myelin and Campylobacter
preparations does not exist. Of note, T cell clones against gangliosides have been described69, but
whether these clones cross-react with Campylobacter strains that carry ganglioside-like epitopes
has not been reported.
Strong proliferative responses of primary T cells, in the order of magnitude of a TT response, to
constituents of PNS or CNS myelin have never been shown. In some publications, low but
reproducable and statistically significant responses have been reported. It is unclear which role
these proliferative responses play in pathogenesis. One publication shows a significant response
of PBMC from patients with peripheral neuropathy to a human PNS myelin protein. P0 elicited a
stimulation index >2 in 6/19 GBS patients tested10. Because in our study one GBS patient, one
CIDP patient, and one control reacted to a P0-containing fraction, we consider our data not in
conflict with this publication. The same authors noted responses to P2 in patients with peripheral
neuropathy and controls and conclude that the immune responses in peripheral neuropathy is
heterogeneous, which is also suggested by our data.
The current techniques and ideas that are used to address this issue are clearly limited. New
technical and theoretical approaches may include a closer look at T-independent B cell activation
or the role of innate immunity in this disease. Also, research in the field of regulatory immune
responses that may prevent tissue damage may prove useful. Some new insights are provided by
recent developments in the field of cytokine expression. Vδ1-expressing γδ T cell clones from
GBS patients appear to express Th2 cytokines stronger and at a higher frequency than Vδ1 clones
from other sources88. γδ T cells, showing signs of recent activation in GBS patients, do not
recognize peptides presented by MHC, indicating that other antigens may play a role in the
development of GBS89. Additional input from, for example, work on T cell independent B cell
activation, other innate immune responses, or a combination of these, may refine the view that
anti-myelin autoimmunity is mainly caused by the wrong adaptive T cell response.
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Vigorous and oligoclonal expansion of human blood γδ  T cells after
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Abstract
Campylobacter jejuni is currently the prime cause of food-borne bacterial gastro-enteritis. An
important complication of C. jejuni enteritis is Guillain-Barré syndrome (GBS), an immune-
mediated disorder of peripheral nerve. It has been suggested that molecular mimicry plays a role
in the pathogenesis of GBS, based on the observation that antibodies against C. jejuni
lipopolysaccharide (LPS) crossreact with several components in peripheral nerve. Because little is
known about T cell reactivity to C. jejuni, we have analyzed the in vitro immune response of
normal individuals against five isolates of C. jejuni representing five different serotypes. We
found a preferential expansion of peripheral blood γδ T cells after exposure to crude sonicates of
all five C. jejuni serotypes. Expansion of γδ T cells was dependent on the presence of CD4+/+
T cells in the cultures or addition of exogenous IL-2 or IL-15. C. jejuni stimulation was mediated
via the T cell receptor and appeared to be induced by a non-proteinaceous bacterial antigen, most
likely of phosphoantigenic origin.
Introduction
Campylobacter jejuni is the leading cause of bacterial food-borne diarrheal disease throughout the
world90. Elevated serum IgG antibodies against C. jejuni, suggestive of previous exposure to C.
jejuni, can be found in 90% of the healthy population91. Humans are usually infected by
consumption of contaminated poultry, milk products or water, frequently resulting in
inflammatory gastro-enteritis in naïve individuals. An important complication of C. jejuni
enteritis is Guillain-Barré syndrome (GBS), an acute inflammatory demyelinating polyneuropathy
which is the leading cause of acute flaccid paralysis in western countries. It has been postulated
that the pathogenesis of GBS involves molecular mimicry because sera of patients with C. jejuni
associated GBS have high titers of antibodies against peripheral nerve gangliosides71;92;93, and the
LPS from various C. jejuni serotypes contain a terminal tetrasaccharide identical to that of the
GM1 or GQ1b ganglioside94. It has been suggested that these cross-reactive antibodies mediate
the immune-related destruction of peripheral nerve tissue in GBS and that the diversity of clinical
features may relate to the serotype of C. jejuni12. Serotype O:1911;95 and O:4112 are over-
represented in GBS patients in Japan and South Africa respectively.
Although the humoral immune response to C. jejuni and the occurrence of crossreactive
antibodies to peripheral nerve tissues has been addressed in many studies, relatively little is
known about the role of T lymphocytes in GBS. Histological studies of peripheral nerve from
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patients with GBS show evidence for T lymphocytes infiltrating the affected tissue1;96;97 and
evidence for the presence of activated T cells and T cell products in the blood and serum has been
found4;5;98. Interestingly, a T cell line established from a nerve biopsy of a patient with GBS with
preceding C. jejuni infection was shown to consist entirely of T cells expressing the γδ TCR99. In
vitro stimulation of blood mononuclear cells from GBS patients, gastroenteritis patients and
healthy volunteers with C. jejuni yielded T cell lines that were enriched for γδ T cells100.
As a prelude to studies on the role of C. jejuni-reactive T cells in patients with GBS, we have
analyzed the in vitro immune response of healthy individuals against five isolates of C. jejuni
representing five serotypes and obtained from both GBS patients and uncomplicated enteritis
patients.
Materials and Methods
Bacterial strains and antigen preparation
A C. jejuni strain was isolated from the stool of a GBS patient and was serotyped as O:2
according to the system described by Penner101. C. jejuni strains with serotypes O:1 (#43429),
O:18 (#43446), and O:19 (#43445) were obtained from the American Tissue Culture Collection
(Manassas, VA). A strain with serotype O:4 (#10938) was from the Culture Collection University
of Göteborg (Göteborg, Sweden). C. jejuni strains were cultured under micro aerobic conditions,
at 37ºC, on Blood Free Campylobacter Selective Agar Base (Oxoid, Basingstoke, Hampshire,
England) supplemented with Cefoperazone (32mg/litre) and Amphotericine B (5mg/litre).
Bacteria were scraped off the plates, washed twice in PBS, and heated at 100º C for 40 minutes,
followed by probe sonication for two minutes. The protein concentration of the preparation was
assessed by the DC Protein Assay (Bio-Rad, Hercules, CA).
LPS was extracted from C. jejuni by the phenol-water method as described by Westphal102. In
short, crude antigen preparations were extracted at 100° C in a mixture of water and phenol. The
aqueous phase was dialyzed against water, centrifuged at 300.000 g for 2 hours, and freeze-dried.
The pellet was weighed and dissolved in water at a concentration of 1mg/ml. The LPS content
was analyzed by SDS-PAGE. Preparations that contained no detectable protein were used for T
cell stimulation studies.
Isopentenyl pyrophosphate (Sigma, St. Louis, MO) was dried under a stream of nitrogen,
dissolved in medium by water bath sonication, and used at 15 µg/ml.
Partial characterization of C. jejuni preparations
Aliquots of delipidated preparations of C. jejuni containing 150-200 µg of protein were treated
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with 1 µg proteinase K (Boehringer-Mannheim, Almere, The Netherlands) for 30 minutes at 37º
C and for 5 minutes at 70º C. This procedure was repeated twice. Subsequently 1 µg pronase E
(Boehringer-Ingelheim, Heidelberg, Germany) was added and incubated at room temperature for
1 hour. The enzymes were finally inactivated at 100º C for 5 minutes.
SDS-PAGE
SDS-PAGE was performed on 14% polyacrylamide gels using the mini protean II system of Bio-
Rad. One hour electroblotting on nitrocellulose membrane (Bio-Rad) was carried out using the
mini transblot system (Bio-Rad). Antigen preparation containing 15 µg of protein, the equivalent
amount of protease-digested antigen preparation, or 1 µg LPS was run per lane. Blots were
stained with Coomassie Brilliant blue for protein detection or with a silver stain kit (Novex, San
Diego, CA), modified after Tsai103 for detection of LPS.
Determination of anti-C. jejuni antibodies in serum
Serum from healthy donors was used in serial dilutions in an ELISA to determine the presence of
IgM, IgG and IgA anti-C. jejuni antibodies91. Ratios were obtained by comparing with negative
reference serum. IgM or IgA ratios >1 were considered to be indicative of recent C. jejuni
infection, and IgG ratios of >2 in the absence of IgM or IgA antibodies indicative of previous C.
jejuni infections in a more distant past91.
T cell cultures and proliferation assays
For proliferation assays, peripheral blood mononuclear cells (PBMC) from healthy donors lacking
IgM or IgA anti-C. jejuni antibodies but with IgG ratios >2 were used. PBMC were isolated from
heparinized blood by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density centrifugation
and resuspended in culture medium consisting of RPMI 1640 (Life Technologies, Paisley,
Scotland) supplemented with L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin and 5%
heat inactivated pooled human AB serum. For proliferation assays, serial 7-fold dilutions of
antigen were added to triplicate wells in roundbottom 96-wells microtiter plates containing 105
cells. At day 5 (PBMC) or day 3 (clones) of culture, 1 µCi of [3H]thymidine was added. After 18
hours cells were harvested onto filters and counted in a β-counter. PBMC were cultured for 12
days prior to flow cytometric analysis. The final antigen concentration in these T cell cultures
corresponded with 3 µg protein/ml. For inhibition assays, 20 µg/ml monoclonal antibody against
the γδ TCR, IL-2 or IL-15 was added to the cultures at days 1, 3, and 6. Human IL-2 was obtained
from Strathmann Biotech (Hannover, Germany) and used at 10 U/ml, and IL-15 was from
PeproTech (Rocky Hill, NJ) and used at 10 ng/ml.
Cloning and restimulation was performed at 17 days after the last stimulation, using irradiated
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allogeneic PBMC as feeder cells, 10 ng/ml IL-15, and antigen at 3 µg protein/ml. Note that PHA
was not used. Proliferation assays were performed without cytokines.
Cell depletion and sorting
For depletion experiments, PBMC from individuals with γδ T cells that were >90% CD4-/CD8-
were used. CD4+ or CD8+ cells were removed from PBMC by incubation with anti-CD4 or anti-
CD8 antibody and magnetic M450 Dynabeads coated with goat anti-mouse IgG (Dynal, Oslo,
Norway), according to the manufacturers protocol. CD4+, CD14+, CD16+, CD19+, CD33+,
Vα24-, and αβ TCR+ populations were depleted from PBMC by cell sorting on a FACStarplus cell
sorter (Becton Dickinson, San Jose, CA). PBMC populations depleted for a population of cells by
magnetic beads or cell sorting contained less than 1% of the depleted population as determined by
flow cytometry.
Monoclonal antibodies and flow cytometry
Anti-human IL-2 (clone B-G5) and IL-15 (clone 34593.11) monoclonal antibodies for use in cell
culture were purchased from Diaclone (Besancon Cedex, France), and from R&D systems
(Minneapolis, MN) respectively. The anti-γδ TCR monoclonal antibody producing hybridoma
5a6.e9 was obtained from the ATCC (Manassas, VA). Hybridoma culture supernatant was
purified on a protein A column (Bio-rad, Hercules, CA), according to the manufacturers protocol.
The protein concentration of the preparation was assessed by the DC Protein Assay (Bio-Rad,
Hercules, CA). Isotype control Ig was obtained from ICN Biomedicals (Eschwege, Germany).
For flow cytometry, anti-CD3 monoclonal antibody conjugated to PECy5 and unconjugated anti-
Vα24 were obtained from Immunotech (Marseille, France), unconjugated anti-Vδ1 (clone A13)
was a gift of Dr L. Moretta, (Genova), unconjugated anti-Vδ2 (clone 4G6), anti-Vγ4 (clone 4A11)
and anti-Vγ9 (clone B3) were gifts of Dr G. De Libero (Basel), unconjugated anti-CD4 was from
Dako (Glostrup, Denmark), goat anti-mouse-PE was from Southern Biotechnology (Birmingham,
Alabama) and all other antibodies were from Becton Dickinson (San Jose, CA). 105 freshly
isolated or cultured cells from 24 pooled wells were used for each staining. All monoclonal
antibody incubations were carried out on ice. Washing of cells and dilutions of antibodies were
carried out with PBS containing 1% BSA. The unconjugated antibodies were used undiluted and
removed by washing before incubation with goat anti mouse-FITC (1:50) or goat anti mouse-PE
(1:500). Cells were washed again and incubated with normal mouse serum (1:1000) before anti
CD3-PECy5 was added. Flow cytometric analysis was performed on a FACScan (Becton
Dickinson).
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Calculation of the T cell expansion index
The expansion of γδ T cells was monitored by flow cytometric analysis as described104 with minor
modifications. Stimulated cells were double-stained with anti-γδ TCR or anti-αβ TCR antibodies
in combination with an anti-CD3 antibody, and the frequency of γδ or αβ cells in the CD3 and
life gate was determined. The absolute number of γδ or αβ T cells was calculated by multiplying
the total number of viable cells in a culture with the frequency of γδ or αβ T cells. The expansion
index was calculated by dividing the absolute number of γδ or αβ T cells at day 12 of culture by
the absolute number of γδ or αβ T cells seeded at the onset of culture.
PCR and nucleotide sequence analysis of TCR Vδ regions
Cultures with expanded populations of TCR Vδ2+  T cells after stimulation with the C. jejuni O:1
antigen were harvested, processed for nucleotide sequence analysis of expressed Vδ2 genes, and
compared to nucleotide sequences expressed in TCR Vδ2+  T cells at the onset of the culture.
RNA extraction was performed with Dynabeads Oligo(dT)25 (Dynal, Oslo, Norway) according to
the manufacturers protocol, followed by two washes in 1* AMV-RT buffer (Boehringer
Mannheim). After the last wash 1 µl RNAguard, 8.5 µl water, 5 µl DTT (100 mM), 5 µl dNTP
(10 mM), 5µl 5* AMV-RT buffer and 0.5 µl AMV-RT were added and incubated at 42º C for
90min for cDNA synthesis.
PCR conditions and primers were identical to those described previously105;106. PCR products
were ligated in the pGEM-T Vector (Promega, Madison, WI) and transformed into E. coli.
Plasmid DNA was isolated from randomly-picked bacterial colonies and used for nucleotide
sequence analysis. The T7 promoter primer was used for sequencing with the Terminator Ready
Reaction DyeDeoxy Cycle Sequencing Kit (Perkin-Elmer Applied Biosystems, Foster City, CA).
Samples were analyzed by automated fluorescence detection.
Clones that were not recognized by the anti-Vδ2 antibody 4G6, nor by the anti-vδ1 antibody A13,
were analyzed by Vδ2 PCR as described. Amounts of cDNA were standardized in an β-actine
PCR.
Results
Crude preparations of C. jejuni induce vigorous T cell proliferation
PBMC from four different healthy donors, with no serological evidence of a recent C. jejuni
infection, were stimulated in vitro with serial dilutions of crude antigen preparations of C. jejuni
isolates of five different serotypes. Representative dose-response curves of a single donor
Figure 1
41
stimulated with the five C. jejuni serotypes and of four donors responding to a single C. jejuni
serotype are shown in Fig. 1. In all experiments, significant proliferation (> 3 times the
background of non-stimulated cells) was observed at protein concentrations as low as 8.7 ng/ml or
less. Maximum proliferation was observed at 3 or 21 µg/ml. Using [3H]thymidine incorporation
as a read-out, only minor differences in the dose-response curves upon stimulation with different
C. jejuni serotypes were observed (Fig. 1). In 40 individuals analyzed to date, we have found only
a single individual that completely and repeatedly failed to respond to all five C. jejuni isolates
(results not shown).
Crude preparations of C. jejuni induce selective outgrowth of γδ T cells
For identification of the proliferating cells in the cultures stimulated with C. jejuni crude antigen
preparations, PBMC at the onset and after 12 days of culture were double-stained with γδ or 
TCR-specific antibodies in combination with an anti-CD3 monoclonal antibody and analyzed by
flow cytometry. The expansion index was calculated by dividing the absolute numbers of
γδ Τ cells before and after stimulation and provides a direct measure of T cell expansion during
culture. In all donors tested, the frequency of circulating γδ T cells was in the normal range,
varying between 0.5 and 10% of the total CD3+ T cell population (not shown). Selective
outgrowth of γδ cells, and minimal or no outgrowth of αβ T cells was induced upon stimulation
of PBMC of 4 healthy donors with crude preparations of all five isolates of C. jejuni. A
representative flow cytometric analysis of T cells before and after cell culture is shown in Fig. 2a.
The results of these experiments, expressed as γδ or αβ T cell specific expansion indices, are
summarized in Table 1. The γδ T cell-specific expansion index ranged from 2 to 151 (median
11.5), whereas the expansion index of αβ T cells in the cultures was significantly lower, ranging
from 0.8 to 2.9 (median 1.6).
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Figure 1
[3H]thymidine incorporation after
stimulation of PBMC from donor
M with different concentrations of
crude C. jejuni preparations of five
different Penner serotypes (panel
a). Variability in the responses of
donor T, Z, M, and I to stimulation
with the O:19 strain is illustrated
in panel b.
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Expansion indices of αβ and γδ T cells after 12 day culture of PBMC of four healthy donors with crude
preparations of five different C. jejuni isolates.
Donor
T cell population                        
Bacterial strain
O:1 4.9 2.9 4.1 1.3 2.0 1.4 20.6 1.6
O:2 29.3 2.0 9.0 0.8 5.9 1.0 15.3 1.0
O:4 13.4 2.2 6.8 1.4 5.5 1.7 11.6 2.2
O:18 27.0 2.2 10.7 1.5 4.9 2.0 31.6 2.2
O:19 151.3 2.1 7.4 1.0 12.5 1.3 32.7 1.2
 Donor Z   Donor T   Donor R Donor M
Table 1    αβ and γδ T cell expansion
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Figure 2
Flowcytometric analysis of PBMC of donor Z
and M at the onset and after 12 days of culture
with C. jejuni. Cells from triplicate or more
wells were pooled and double-stained with the
CD3-PECy5 and pan γδ TCR-F monoclonal
antibodies (panel a), or with the CD3-PECy5 in
combination with the Vδ1-F, Vδ2-F, Vγ4-F, or
Vγ9-F antibodies (panel b). Percentages of γδ T
cells are expressed as percentages within the
live, CD3+ population. Note that the sum of the
two Vγ families does not match the total
amount of γδ T cells of donor M at day 12, as
determined by the pan γδ TCR antibody.
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Vγ and Vδ chain utilization in γδ T cells stimulated with C. jejuni
TCR Vγ and Vδ utilization among γδ T cells before and after stimulation with crude preparations
of C. jejuni was analyzed by flow cytometry using monoclonal antibodies specific for Vγ4, Vγ9,
Vδ1, and Vδ2, and a pan-γδ Τ cell receptor monoclonal antibody. In three of the four donors
analyzed (T, R and Z), the number of (Vδ1+ plus Vδ2+) and (Vγ4+ plus Vγ9+) cells matched the
number of γδ T cells detected with the pan-γδ TCR antibody. The results obtained with donor Z
are shown in Fig. 2, upper panels. In donor M, the number of γδ T cells detected with the pan-γδ
TCR antibody exceeded the sum of the individual Vγ  and Vδ families, suggesting the expansion
of γδ Τ expressing V regions not detected with the available monoclonal antibodies (Fig. 2 lower
panels).
In donor T, Z, and I, prior to culture 95%, 56%, and 53% of the peripheral blood γδ T cells
respectively expressed a TCR encoded by the Vδ2 and Vγ9 gene segments. After culture with all
five serotypes of C. jejuni, the Vδ2/Vγ9 combination was expressed by virtually all γδ T cells. A
representative experiment is shown in Fig. 3. In donor M, a different pattern was observed. In this
donor we observed outgrowth of T cells expressing Vδ1 in combination with a Vγ gene segment
not identified with our monoclonal antibodies after stimulation with four of the serotypes, and
outgrowth of an undetermined Vδ in combination with Vγ9 after stimulation with the fifth
serotype. γδ T cells in the non-stimulated PBMC of this donor expressed TCR encoded by Vδ2
(24%) and Vδ1 (76%) showing that T cells expressing the undetermined Vδ comprised only a
minor population at the onset of culture. PCR analysis of RNA extracted from γδ T cells clones
that were not recognized by the anti-Vδ1 and the anti-Vδ2 antibodies showed that they all express
a Vδ2 chain (not shown).
Figure 3
Vγ and Vδ gene utilization in γδ T
cells before and after in vitro
stimulation with C. jejuni. V gene
families showing less than 5%
increase after the cultures are not
shown. Representative data of the
PBMC of two donors, stimulated
with three different crude C.jejuni
serotypes are shown.
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Expanded γδ T cells of all donors, stimulated with all bacterial strains were mostly CD4-/CD8-
with a variable percentage (range 0-35%) CD4-/CD8+ γδ T cells (not shown).
Nucleotide sequence analysis of TCR Vδ regions
We assessed the clonal diversity of γδ T cells proliferating in response to in vitro stimulation with
C. jejuni. Freshly-isolated PBMC from donor R and Z were were compared to cultures that had
been stimulated for 12 days with the crude antigen preparation of C. jejuni strain O:1. The cells
were used for RNA extraction and first strand cDNA synthesis and amplified with a Vδ2 specific
primer pair. PCR fragments were cloned and the nucleotide sequence of 80 independent Vδ2
inserts was obtained comprising 40 inserts from each donor, equally divided between PBMC
before and after culture. The Vδ-Dδ-Jδ junctional sequences are shown in Table 2. All Vδ2
sequences analyzed were in frame. In the collections of 20 sequences from freshly-isolated
PBMC, all sequences from donor Z and 19/20 sequences from donor R were unique. After
culture, the collections of Vδ2 sequences of the two donors (R and Z) showed clear evidence of
oligoclonal expansion as evidenced by the recurrence of identical Vδ-Dδ-Jδ junctional sequences
in independently picked bacterial clones.
The C. jejuni antigen with strong γδ T cell-stimulatory capacity is a protease resistant
compound
Human γδ T cells have been reported to respond to a wide variety of antigens. To determine the
nature of the antigen with strong γδ T cell-stimulatory capacity, crude C. jejuni preparations were
subjected to a number of treatments and separation procedures.
LPS, known to stimulate murine γδ T
cells107, was isolated from C. jejuni
isolates O:1 and O:2 by phenol-water
extraction and identified on silver
stained SDS-PAGE gels (Fig. 4, right
panel). In dose-response curves with
concentrations ranging from 1.2 ng/ml
to 3 µg/ml, LPS induced a just above
background proliferative response in 12 day cultures of PBMC. At day 12 of culture, no γδ T cells
were detectable by flow cytometry (results not shown), indicating that LPS is not the compound
responsible for the γδ T cell response to C. jejuni antigen preparation.
The crude antigen preparations of serotypes O:8 and O:19 were delipidated, treated with pronase
E and proteinase K and analyzed by SDS-PAGE to monitor the efficiency of protein degradation.
Figure 4
Protease-treated (left panel, left
lane) and untreated (left panel,
right lane) C. jejuni O:19
antigen preparation on a
Coomassie stained blot, and
phenol-water extracted LPS of
O:1 and O:19 on a silver stained
gel (right panel).
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Freq. DV N DD1/N/DD2 N DD3 N DJ1/DJ2/DJ3 CDR3
Donor R, unstimulated
2\20 cctgtgac cgg atatcctac actgggg cca acaccgataaactcat  DJ1 13
1\20 cctgtgac tcta t actggggga     cgataaactcat  DJ1 9
1\20 cctgtgacacc atagcatcct cttt actgggggata ggaggag  caccgataaactcat  DJ1 17
1\20 cctgtgacacc ctac   tggg aa acaccgataaactcat  DJ1 10
1\20 cctgtgacacc g   tgggg actaag   accgataaactcat  DJ1 10
1\20 cctgtgacacc gtgg gaagt actgggg aacg  caccgataaactcat  DJ1 13
1\20 cctgtgac ccccgagc ccttccta aa actgggggatac acgaaggg     cgataaactcat  DJ1 17
1\20 cctgtgac tcct t actgggggatacg cgggggt acaccgataaactcat  DJ1 14
1\20 cctgtgacacc ggaggttatt  ctgggg   cctgggacacccga  DJ3 14
1\20 cctgtgacacc acaggctac g  ctgggg cttcgg    ccgataaactcat  DJ1 13
1\20 cctgtgacacc gtaaaga ctac gtcgcct actgggggatacg aggggt acaccgataaactcat  DJ1 19
1\20 cctgtgac ccactggggcgagga ccta gg actgggg aaaaaac  caccgataaactcat  DJ1 17
1\20 cctgtgacac tt     gggga ctccgggaggg        taaactcat  DJ1 10
1\20 cctgtgacacc ttaggtgtc     ggggatacg gaaatta acaccgataaactcat  DJ1 15
1\20 cctgtgaca attt actggggg cca acaccgataaactcat  DJ1 11
1\20 cctgtgac ggga   tgggggatac tctct ctttgacagcacaact  DJ2 13
1\20 cctgtgacac g   tggggga acaccgataaactcat  DJ1 9
1\20 cctgtgacacc gaa     gggga caggggggg     cgataaactcat  DJ1 11
1\20 cctgtgacacc    gggggatac aag   accgataaactcat  DJ1 10
Donor R, after stimulation with O:1
5\20 cctgtgacacc gtggg tag gta   tgggg cgaccgaaaacggg         aaactcat  DJ1 14
3\20 cctgtgac tcac tcc ga     ggggatacg cgaattcgcgggac  caccgataaactcat  DJ1 16
3\20 cct cct cacaccg    ggggga gggtggggatctc         aaactcat  DJ1 11
1\20 cctgtgac tcactccga     ggggatacg cgaattcgcgggac  caccgataaactcat  DJ1 16
1\20 cctgtgac ccagt gaaaattccta tatcggt actgggggatac caggggg   accgataaactcat  DJ1 19
1\20 cctgtga tcc cgt actgggggat ggaaagt acaccgataaactcat  DJ1 13
1\20 cctgtgacacc g tagttcc c     gggga aaagggac    ccgataaactcat  DJ1 13
1\20 cctgtgacac t ctac c    gggggatac taagag ctcctgggacacccga  DJ3 16
1\20 cctgtgacac actcgg   tgg  caccgataaactcat  DJ1 9
1\20 cctgtgacacc  ctgggggatac caccca  caccgataaactcat  DJ1 12
1\20 cctgtgac ccgcccgt actgggggatacg  tcctgggacacccga  DJ3 15
1\20 cctgtgaca tagttac   tggg cccaccaatt acaccgataaactcat  DJ1 13
Donor Z, unstimulated
1\20 cctgtgacacc gttgg tagt cga      gggat ttttaag         aaactcat  DJ1
1\20 cctgtgac gttc tag gaa   tgggggat cct      gataaactcat  DJ1 11
1\20 cctgtga atcctt aaggacgtccg    gggggatac agttcggg   accgataaactcat  DJ1 16
1\20 cctgtgac tcc  ctggg acta   accgataaactcat  DJ1 9
1\20 cctgtgacac tctt attat   tggggga ac  caccgataaactcat  DJ1 12
1\20 cctgtgac ct actgggggatac gggtgggg       ataaactcat  DJ1 11
1\20 cctgtgacacc cttcttcctac cgtg actgg acctgt  caccgataaactcat  DJ1 15
1\20 cctgtgacacc gttat tag   tgggggatac tccgaactacacg    ccgataaactcat  DJ1 16
1\20 cctgtgacacc g tagttcc c     gggga aaagggac    ccgataaactcat  DJ1 13
1\20 cctgtgacacc g tag g actgggggatacg cgggatactggggcgac           actcat  DJ1 15
1\20 cctgtgac cccgccggt actggggg tttgt acaccgataaactcat  DJ1 13
1\20 cctgtgacac actagaca gaaa c     gggga actttccgaat acaccgataaactcat  DJ1 16
1\20 cctgtgac gacatcc gga    ggg ccaagt acaccgataaactcat  DJ1 12
1\20 cctgtgac tcggc     ggggatacg ctct      gataaactcat  DJ1 10
1\20 cctgtgaca gtattaccg   tgggggat ggcct        taaactcat  DJ1 11
1\20 cctgtga tcc ggtggag    ggggga ctggagg    ccgataaactcat  DJ1 12
1\20 cctgtgacacc ctcggg actgggg acctaagaaa     cgataaactcat  DJ1 13
1\20 cctgtga tgggtt actgggggata taggtatca       ataaactcat  DJ1 12
1\20 cctgtgacacc gtaggg gaa g  ctggggg caaa   accgataaactcat  DJ1 13
1\20 cctgtgac cat  ctggg tgatacaa acaccgataaactcat  DJ1 11
Donor Z, after stimulation with O:1
5\20 cctgtgacacc gtc      ggga ccc acaccgataaactcat  DJ1 10
3\20 cctgtgacac gt   tggggg acaccgataaactcat  DJ1 9
3\20 cctgtgac ccat   tggggg ccct     cgataaactcat  DJ1 9
2\20 cctgtgacacc   tgggg accg   accgataaactcat  DJ1 9
1\20 cctgt att  ctggggga catgt acaccgataaactcat  DJ1 10
1\20 cctgtgacacc g   tgggg ccccgggg ctcctgggacacccga  DJ3 14
1\20 cctgtgacacc gtgggt actgggggatacg cgttg      gataaactcat  DJ1 13
1\20 cctgtgac ctacttcttcc cgcgg   tggggga acct acaccgataaactcat  DJ1 15
1\20 cctgtgac gc  ctggggg ccgtat   accgataaactcat  DJ1 10
1\20 cctgtgac ccgatcc caat      ggga gagggtcgtt acaccgataaactcat  DJ1 14
1\20 cctgtga tccc         atac tgacc        gacacccga  DJ3 10
Table 2 VDJ sequences derived from donor R and Z, before and after in vitro stimulation with C. jejuni.
46
After blotting and Coomassie Brilliant blue staining, no protein could be detected (Fig. 4, left
panel, left lane). PBMC from a healthy donor were stimulated with mock-treated or protease-
treated antigen preparations and a [3H]thymidine incorporation assay and flow cytometric analysis
were performed. No differences in the proliferation-inducing capacity between the mock-treated
and the delipidated/protease-treated C. jejuni preparations was observed (Fig. 5 upper panel).
Flow cytometric analysis showed that stimulation of PBMC with either preparation resulted in the
selective and extensive expansion of γδ T cells (Fig. 5 lower panel).
Reactivity of γδ T cell clones and C. jejuni stimulated cell lines
We generated polyclonal cell lines from PBMC of three different donors by two cycles of
stimulation with C. jejuni antigen. Clones were obtained from these cell lines, and polyclonal
lines and clones were tested for reactivity with C. jejuni or isopentenlyl pyrophosphate (IPP). All
cell lines proliferated in response to stimulation with C. jejuni and IPP. These results were
confirmed by the proliferative response of three independent clones from two of the donors
(Figure 6).
Figure 6
Proliferation of a polyclonal cell line and three
independent clones to C. jejuni and IPP stimulation.
Clones m2 and d62 are derived from different donors and
are Vδ2 positive as they stain with the 4G6 antibody, and
clone m31 gives a positive Vδ2 PCR signal although it
does not stain with the available antibodies. The
stimulation index is defined as the cpm obtained from
wells with responder cells, irradiated feeder cells, and
antigen, divided by the cpm from the wells with responder
cell and irradiated feeder cells without antigen.
Figure 5
[3H]thymidine incorporation (a) and FACS analysis
(b) of non-stimulated PBMC of donor R (left panel)
and PBMC stimulated with mock-treated (middle
panel) or protease-treated/delipidated serotype O:19
C. jejuni preparations (right panel). Both mock and
protease-treated/delipidated preparations induced
selective outgrowth of γδ T cells, as shown by flow
cytometric analysis of CD3-PECy5/pan γδ TCR-F
stained cells (b).
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The presence of CD4+/αβ T cells is a prerequisite for the γδ T cell response to C.
jejuni
To determine whether signaling via the γδ T cell TCR was essential for the observed stimulation
of γδ T cells by C. jejuni, we administered a blocking anti-γδ TCR antibody108 to the cultures. As
shown in Fig. 7, control antibody does not influence the response of γδ T cells to C. jejuni,
whereas the anti-γδ TCR 5a6.e9 monoclonal antibody completely abolishes γδ T cell expansion.
It has been shown that γδ T cell expansion of PBMC upon stimulation with Daudi cells109 or
Mycobacterium tuberculosis110;111 depends on the presence of CD4+ cells. To determine the
contribution of CD4+ cells to the response to C. jejuni, PBMC were depleted with CD4 or CD8
monoclonal antibody-coated magnetic beads and subsequently stimulated with C. jejuni.
Depletion of CD8+ cells did not affect the proliferative response to C. jejuni, whereas depletion of
CD4+ cells completely abrogated γδ T cell expansion (Fig. 8). These findings were extended by
depleting PBMC of a number of cell subpopulations by cell sorting. Thus, depleting PBMC of
TCR+ T cells or CD4+ cells completely abrogated the proliferative response, whereas
depletion of CD14+/CD16+, CD33+, CD19+, or V24+ cells had no effect (Fig. 9).
Figure 7
The γδ T cell response to stimulation with
C. jejuni serotype O:18 is inhibited by
addition of 20 µg/ml anti-γδ TCR
monoclonal antibody but not by isotype-
matched control monoclonal antibody.
The γδ T cell expansion index of different
donors in response to C. jejuni O:18
stimulation is depicted.
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Figure 8
Immunomagnetic depletion of CD4+ cells, but not of CD8+ cells from
PBMC of two different donors abrogated the response to C. jejuni O:19
antigen (a) and O:2 antigen (b). The response could be restored by the
addition of 10 U/ml IL-2 (a and b) or 10 ng/ml IL-15 (b). Dashed bars
represent the γδ T cell specific expansion index, and open bars the αβ T
cell specific expansion index. The results are representative of experiments
with PBMC from eight different donors.
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The γδ T cell response to C. jejuni can be restored by adding IL-2 or IL-15 to CD4-
depleted cultures of PBMC
The role of the T cell growth factors IL-2 and IL-15 was assessed by adding these cytokines to
CD4-depleted cultures of PBMC stimulated with crude C. jejuni preparations. Low doses of both
IL-2 and IL-15 were capable of restoring the γδ T cell response in CD4-depleted populations (Fig.
8). As noted previously by others112;113, γδ T cells from some donors proliferated in response to
stimulation with IL-2 alone, in the absence of C. jejuni antigen (results not shown). We did not
include these donors in these experiments.
Monoclonal antibodies to IL-2 and IL-15 unveil a dichotomy in cytokine
production in cultures of C. jejuni stimulated PBMC
The observation that low doses of IL-2 and
IL-15 restored the γδ T cell response to C.
jejuni in CD4-depleted PBMC populations
were further supported by the finding that
anti-IL-2 monoclonal antibody and in some
donors the combination of anti-IL-2 and anti-
IL-15 antibodies blocked the γδ T cell
response to C. jejuni when total PBMC were
stimulated (Fig. 10). Anti-IL-15 antibodies
alone did not affect the γδ T cell response in 6
donors tested.
Figure 9
The γδ T cell expansion indices of C. jejuni
strain O:1-stimulated PBMC from donor A
and B, depleted for αβ TCR+, CD4+,
CD14+/CD16+, CD33+, and CD19+ cells by
cell sorting. As a control for the sorting
procedure, unstained PBMC were run
through the sorter and put in culture. In
separate experiments with PBMC from donor
C and D, the NKT cell population was
depleted from the PBMC with an anti-Vα24
antibody (right panels).
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Figure 10
Inhibition of the γδ T cell response by anti-IL-2
monoclonal antibody (donor L), or a combination of anti-
IL-2 and anti-IL-15 monoclonal antibodies (donor S). The
γδ T cell expansion index of different donors in response to
C. jejuni O:18 stimulation is depicted. Results are
representative of experiments with PBMC from six donors.
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Discussion
C. jejuni has become recognized as the most frequent antecedent pathogen associated with the
development of GBS. Although the humoral immune response to C. jejuni and the occurrence of
cross-reactive antibodies to peripheral nerve tissues has been addressed in many studies, relatively
little is known about the role of T lymphocytes in GBS. We therefore analyzed the human T cell
response to crude preparations of five different serotypes of C. jejuni.
The results presented here show that all five different serotypes of C. jejuni induce in vitro
proliferation of γδ T cells present in PBMC from healthy individuals. In 40 individuals analyzed
to date, we found only a single individual that completely and repeatedly failed to respond to all
five C. jejuni serotypes.
In three out of four donors extensively analyzed here, stimulation with all five C. jejuni serotypes
resulted in the expansion of T cells expressing the Vγ9/Vδ2 TCR. In the fourth donor,
proliferation of T cells expressing Vδ1 and an undetermined Vγ  was observed. The Vγ9/Vδ2 T
cell receptor pair is utilized in 50-75% of circulating γδ Τ cells, whereas the second major
population of blood γδ Τ cells expresses Vδ1 in combination with one of several Vγ gene
segments114. Expansion of circulating Vδ1 expressing T cells has only occasionally been reported
in the context of HIV115;116 and CMV after renal transplant117. Vγ9/Vδ2 T cell expansions are
associated with many human infectious diseases including EBV-mononucleosis118, CMV
disease119, tuberculosis120, tularemia121, listeriosis122, toxoplasmosis123, salmonellosis124, and
infection with Coxiella burnetii125. EBV and CMV are two pathogens that are also frequently
found in association with GBS.
Previous reports have shown that the Vγ9/Vδ2 T cells expanding in vitro in response to crude
preparations of Mycobacterium tuberculosis show extensive Vδ-Dδ-Jδ junctional diversity,
reflecting a polyclonal T cell response126;127. In contrast, nucleotide sequence analysis of 80 Vδ2
regions of Vγ9/Vδ2 T cells in the two donors analyzed here before and after stimulation with C.
jejuni provided evidence for an oligoclonal T cell outgrowth.
It has been previously shown that CD4+ T cells provide helper functions for the expansion of
γδ Τ cells induced by mycobacterial extracts110;111;128. Similarly, the proliferation of C. jejuni-
reactive γδ T cells could be completely abrogated by depleting CD4+ T or  TCR+ T cells
from PBMC. Depletion of other cell types including B cells, NK cells, dendritic cells, monocytes,
and NKT cells did not impair the ability of γδ Τ cells to respond to C. jejuni stimulation. The γδ T
cell proliferation in CD4- or  TCR-depleted PBMC could be completely restored by addition
of IL-2 to C. jejuni stimulated cultures, confirming previous findings that, at least in vitro, IL-2 is
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a key cytokine for γδ Τ cell expansion provided by CD4+ T lymphocytes110;129. Addition of IL-15,
a T cell growth factor that shares some activities with IL-2 in vitro130, also completely restored γδ
T cell proliferation in CD4-depleted PBMC. This is in line with previous reports that show that
IL-15 contributes to the activation γδ T cells131;132. Of note, recent data show that IL-15 may have
a prominent role in stimulating and maintaining memory T cells in vivo in mice and humans130;133-
135.
Blocking studies with monoclonal antibodies specific for IL-2 and IL-15 in cultures of
unseparated PBMC stimulated with C. jejuni unveiled a dichotomy in cytokine production during
culture of PBMC with crude lysates of C. jejuni. In three out of six donors tested, addition of anti-
IL-2 monoclonal antibodies to the cultures completely inhibited γδ T cell proliferation, whereas
addition of anti-IL-15 antibodies had no effect. In the cultures of PBMC of the remaining 3
donors analyzed, addition of anti-IL-2 or anti-IL-15 antibodies had no effect whereas the
simultaneous addition of both anti-IL-2 and anti-IL-15 antibodies completely inhibited the
outgrowth of C. jejuni-reactive γδ T cells. Apparently, in all donors IL-2 is produced during
culture of PBMC with C. jejuni, requiring at least the addition of anti-IL-2 antibodies to block γδ
T cell proliferation. In cultures of PBMC of a subset of donors, IL-15 appears to be produced in
addition to IL-2, requiring the presence of both anti-IL-2 and anti-IL-15 antibodies for inhibition.
IL-15 may be produced by a variety of cell types including monocytes, dendritic cells and T cells
(reviewed by Fehniger et al.130).
The depletion studies suggest that CD4+ T cells are the source of IL-2 and IL-15 in C. jejuni
stimulated cultures of PBMC. A possible mechanism of CD4+ T cell activation leading to
cytokine production, but not proliferation, in the absence of antigen presenting cells and protein
antigens is activation via immune receptors recognizing more conserved molecules, like the Toll-
like receptor family.
C. jejuni-specific stimulation was mediated via the γδ TCR. We demonstrated that protease
treatment of crude preparations of C. jejuni did not diminish the γδ T cell response further
suggesting that conventional presentation of peptides by antigen presenting cells was not required.
Indeed, a number of non-proteinaceous compounds have been identified that stimulate γδ T
cells24;136-140. Although the stimulatory component for the γδ T cells in the crude preparations of
C. jejuni was not purified in the current studies, the fact that Campylobacter-reactive clones and
cell lines recognize isopentenyl pyrophosphate suggests that the active compound in
Campylobacter antigen preparation is of phosphoantigenic origin.
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Chapter 5
Long-lasting γδ T cell non-responsiveness in patients with
Campylobacter jejuni-associated Guillain-Barré syndrome
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Departments of 1Neurology and 3Immunology University Medical Center Utrecht, 2Departments
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Abstract
Guillain-Barré syndrome (GBS) is an acute, autoimmune neuropathy. Two thirds of the GBS
patients report an acute antecedent infectious disease, most frequently Campylobacter jejuni
enteritis. Serum antibodies against C. jejuni lipopolysaccharides cross-react with peripheral nerve
components, suggesting that molecular mimicry plays a role in the induction of GBS. Here, we
aimed to seek further evidence for this hypothesis by studying C. jejuni-reactive T lymphocytes in
GBS patients. PBMC of GBS patients and controls were stimulated in vitro with crude sonicates
of C. jejuni. In healthy individuals, T lymphocytes expressing γδ but not αβ T cell receptors
vigorously proliferated after stimulation with C. jejuni. In contrast, γδ Τ cells of acute GBS
patients with antecedent C. jejuni infections completely failed to respond. GBS patients without
evidence for antecedent C. jejuni infections and individuals with C. jejuni enteritis without GBS
responded like healthy individuals. In some patients, the γδ Τ cell non-responsiveness could last
for years after recovery from GBS. Supplementing cell cultures with the cytokines IL-2 or IL-15
resulted in restoration of the γδ Τ cell proliferative response. γδ T cell non-responsiveness in GBS
patients reflects a lack of production of cytokines required to activate γδ T cells. T cell non-
responsiveness and ensuing defective autoimmune regulation may be a more general mechanism
leading to autoimmune disease.
Introduction
Guillain-Barré syndrome (GBS) is the leading cause of acute flaccid paralysis in most countries.
GBS occurs worldwide and affects patients of all ages. In approximately two-thirds of patients,
the neuropathy is preceded by an infectious illness, most commonly a respiratory-tract infection
or gastroenteritis. Campylobacter jejuni, a gram-negative rod that is a major cause of bacterial
gastroenteritis worldwide, is the most frequent antecedent pathogen70-72.
An autoimmune etiology of GBS has generally been accepted141. Antibodies to nerve components
have been detected in serum of GBS patients, complement deposits and lymphocytic infiltrates
have been observed in sural nerve biopsies and postmortem peripheral nervous system
material1;96;97 and patients have increased levels of circulating IL-2, soluble IL-2 receptors and
activated T lymphocytes4;9;98 Based on the observation that anti C. jejuni lipopolysaccharide
antibodies crossreact with gangliosides in peripheral nerve, it has been suggested that ‘molecular
mimicry’ plays a role in the pathogenesis of GBS94. In this scenario, the immune response to the
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infectious organism would generate antibodies and perhaps T lymphocytes that cross-react with
components of peripheral nerve.
To gain further insight in the role of T lymphocytes in the pathogenesis of GBS, we analyzed the
in vitro response of peripheral blood mononuclear cells from GBS patients with antecedent acute
C. jejuni infections and from GBS patients without evidence of recent exposure to this micro-
organism. As controls, we evaluated the in vitro response of healthy individuals and patients with
a history of C. jejuni-induced enteritis.
Methods
Study subjects
An overview of the clinical status of the GBS patients whose blood was collected for this study is
presented in Table 1. GBS was diagnosed according to established criteria142. Acute phase GBS
patients were included in the study within one week after the diagnosis of disease. None of the
patients received medication at the time blood samples were collected. Experiments with material
from a GBS patient and from a healthy control subject were conducted on the same day. None of
the healthy control subjects recorded recent symptoms of enteritis. Patients with a history of C.
jejuni enteritis, as established by a positive C. jejuni culture from their stool during the acute
phase of gastro-enteritis, were also included in the study. The Medical Ethical Committee of the
University Medical Center Utrecht approved the study protocol.
Serologic studies and criteria for C. jejuni positivity
C. jejuni seropositivity was determined in an ELISA as described91. Acute phase serum of GBS
patients was tested for the presence of anti-C. jejuni IgG, IgA, and IgM. Ratios were determined
by dividing the OD of the serum by the OD of a negative reference serum representing the cut-off
titer.
Patients with positive C. jejuni stool culture, patients suffering from diarrheal disease before
development of GBS and anti-C. jejuni IgG ratios > 8, and patients with anti-C. jejuni IgM or IgA
ratios > 1 were considered as C. jejuni positive. Patients with IgM and IgA ratios < 1 and no
history of diarrheal disease were considered to be C. jejuni negative, irrespective of their IgG
titer71.
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T cell cultures and proliferation assays
Twenty ml heparinized blood from a GBS patient and from a healthy control subject was
collected on the same day and processed in parallel. Blood was diluted 1:1 in PBS and centrifuged
over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) at 900 g during 20 minutes. After two
washes in PBS, the cells were counted and resuspended at 106 cells/ml in culture medium. Culture
medium consisted of RPMI 1640 (Life Technologies, Paisley, Scotland) with L-glutamine, 100
U/ml penicillin, 100 U/ml streptomycin and 5% heat inactivated human pooled serum. An 100 µl
aliquot of the PBMC and 100 µl culture medium with antigen or mitogen at double the final
concentration were mixed in roundbottom 96-wells microtiter plates and cultured during 12 days
prior to cell counting and flow cytometric analysis. For proliferation assays, 1 µCi of 3H labeled
thymidine was added to triplicate wells at day 5 of culture. After 18 hours cells were harvested
Subject Time after Severity C. jejuni CMV EBV Myco- 
onset score plasm 
acute GBS
1/ac acute 5 + - - -
2 acute 4 + - - -
3 acute 3 + - - -
4 acute 3 + - - -
5 acute 4 + - - -
6 acute 4 - - - -
7 acute 3 - - - -
8 acute 2 - - - -
9/ac acute 3 - - - -
10 acute 4 - - - -
 recovered from GBS
1/ex 2 months 5 + - - -
11 7 years 5 + - - -
12 3 years 5 + - - -
13 3 years 3 + - - -
14 3 years 2 + - - -
15 3 months 3 + - - -
16 3 years 2 + + - -
17 7 years 5 + - - -
18 7 years 4 - - - -
19 1 month 3 - - - +
20 4 years 4 - - - -
9/ex 7 months 3 - - - -
recovered from C. jejuni  enteritis
21 4 years +
22 2 years +
23 2 years +
24 1 year +
25 3 years +
Table 1      Study subjects Clinical status of the GBS and
C. jejuni enteritis patients
included in this study. The
period between onset of GBS
or C. jejuni enteritis and
inclusion in our experiments is
depicted as 'Time after onset
disease'. Severity of GBS was
scored at the peak of their
illness on a functional
disability scale on which 0
denotes healthy; 1, minor
symptoms; 2, able to walk > 10
m without assistance; 3, able to
walk > 10 m with support; 4,
bedridden or chairbound; 5,
requiring assisted ventilation
for at least part of the day; 6,
dead. Antibodies against CMV,
EBV, and mycoplasm were not
determined in C. jejuni
enteritis patients.
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onto filter papers and counted in a -counter. Levels of 3H thymidine incorporation in C. jejuni-
stimulated cultures were calculated by subtracting background 3H thymidine incorporation from
cell cultures containing medium without the crude C. jejuni preparations.
The expansion index was calculated by dividing the absolute number of αβ or γδ T cells at day 12
after stimulation by the absolute number at day 0. IL-2 was obtained from Strathmann Biotech
(Hannover, Germany) and used at 10 U/ml, and IL-15 was from Pepro Tech (Rocky Hill NJ) and
used at 10 ng/ml.
Bacterial strains and antigen preparation
For stimulation of cells, eight C. jejuni strains were used. Four C. jejuni strains, differing in their
serotype as described by Penner101. were obtained from the ATCC: ATCC 43429: serotype O:1;
ATCC 43446: serotype O:19; ATCC 43445: serotype O:18; and CCUG 10938: serotype O:4. In
addition, we used four C. jejuni strains isolated from the stool of GBS patients. The serotype of
one of these strains could not be determined and the other strains had serotypes O:1, O:2, and
O:19. C. jejuni strains were cultured under micro aerobic conditions at 37ºC, on Blood Free
Campylobacter Selective Agar Base (Oxoid, Basingstoke, Hampshire, England) supplemented
with Cefoperazone (32 mg/litre) and Amphotericine B (5 mg/litre). When growth was sufficient,
the bacteria were scraped off the plates and washed twice in PBS. The pellet of approximately 0.5
ml was heated at 100ºC for 40 minutes, followed by sonication for two minutes. The protein
concentration of the preparation was assessed by the DC Protein Assay (Bio-Rad, Hercules, CA).
The crude C. jejuni antigen preparations were stored at -20ºC until use. Mycobacterium
tuberculosis strain H37a was obtained from Difco (Detroit, MI). A vial containing 100 mg of dry
material was dissolved in 2 ml water, sonicated, and used at a 1:1000 dilution in T cell cultures.
Antibodies and staining procedures
Anti-CD3-PECy5, goat anti-mouse-PE, unconjugated anti-FasL, unconjugated anti-TCR ζ chain,
unconjugated anti-FasL, and anti-Fas-Fitc were obtained from Immunotech (Fullerton, CA).
Unconjugated anti-TCR Vδ1 (clone A13) was a kind gift of Dr L. Moretta, Genova, unconjugated
anti-TCR Vδ2 (clone 4G6), anti-Vγ4 (clone 4A11) and anti-Vγ9 (clone B3) were generous gifts
of Dr G. De Libero, Basel, anti-CD94 was a kind gift of Dr M Lopez Botet, Madrid, and all other
antibodies were from Becton Dickinson. 105 freshly isolated or cultured PBMC were used per
staining. All incubations were on ice. Washes and dilutions of antibodies were carried out with
PBS containing 1% BSA. The unconjugated antibodies were used undiluted and removed by
washing cells before incubation with goat anti-mouse-FITC (1:50) or goat anti-mouse-PE (1:500).
Cells were washed again and incubated with normal mouse serum (1:1000) before other
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antibodies were added. Flow cytometric analysis was performed on a FACSscan (Becton
Dickinson, Franklin Lakes, NJ) and for each analysis 5000 ungated events were acquired. In the
Figures, the percentage of CD3+ cells is expressed as the percentage of cells within a gate around
the living cells. The γδ TCR+ cells and the Vγ and Vδ families are expressed as percentages of
the living, CD3+ population. In case the number of γδ T cells detected with the pan-γδ antibody
exceeded the sum of the individual Vγ and Vδ families, the presence of γδ T cells expressing a V
region not detected with the available monoclonal antibodies was assumed and termed
'undetermined Vγ or Vδ'. Fas, FasL, CD8, HLA-DR, FcRIII, and CD94 positivity is expressed as
a percentage of the living, CD3+, γδ TCR+ population.
Statistical analyses
The mean of triplicate measurements of 3H thymidine counts and expansion indices was log-
transformed prior to statistical evaluation. Values obtained from culture medium control
stimulations were subtracted from experimental values. We used a two-tailed Mann-Whithney
rank sum test to analyze the differences between healthy control subjects and different patient
groups.
Results
Freshly isolated PBMC were stimulated with crude antigen preparation of eight different C. jejuni
strains at a concentration of 3µg protein/ml that, in preliminary dose-response experiments, was
determined to be the optimal stimulatory dose for all strains. The eight different C. jejuni strains
did not differ in their capacity to stimulate the proliferation of T cells in either patient or healthy
control groups (results not shown). Therefore, the experimental values obtained from stimulations
with different strains were averaged and are referred to as ‘C. jejuni antigenic stimulation’. 3H-
labeled thymidine incorporation was measured at day 5 of the culture, whereas flow cytometric
analysis was performed at day 12.
PBMC of healthy donors (n = 30) vigorously proliferated upon stimulation with crude C. jejuni
preparations (median 30*103 cpm, range 7.6 - 101*103 cpm; Figure 1a). In contrast, PBMC of
acute GBS patients with a preceding C. jejuni infection (n = 5) did not proliferate upon
stimulation with C. jejuni antigen (median 1.2*103 cpm, range 0.12 – 3.2*103 cpm; Figure 1b).
The group of acute GBS patients with a preceding C. jejuni infection differed significantly from
the group of healthy donors in their proliferative response to C. jejuni antigenic stimulation (P <
0.001). PBMC of GBS patients without evidence for antecedent C. jejuni infections (n = 5),
proliferated vigorously in response to C. jejuni stimulation. The magnitude of the response did not
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differ significantly from that of healthy individuals (median 48*103 cpm, range 4.6 – 139*103
cpm, Figure 1b).
To assess whether the observed non-responsiveness was transient, we collected blood of patient 1
two months after the first experiment. In addition, we analyzed seven patients who had a recorded
history of C. jejuni related GBS but were free of symptoms for prolonged periods of time, up till 7
years. Varying responses were observed (n = 8, median 3.9*103 cpm, range 0.2 - 47*103cpm) with
two of the eight recovered patients responding similar to the majority of healthy individuals, three
patients showing a very low response, and three patients showing absence of a γδ T cell response
(Figure 1b). Patients 11 and 17, which were among these low and non-responders, were both free
of clinical signs of GBS as long as 7 years prior to these experiments.
Patients with a history of gastro-enteritis caused by C. jejuni showed high responses (n = 5,
median 52*103 cpm, range 32 - 68*103cpm, Figure 1b ) and differed significantly (P < 0.01) from
this group of recovered, C. jejuni positive GBS patients. The uncomplicated gastro-enteritis
patients had recovered from their disease between one and three years at the time of inclusion in
the experiments.
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Figure 1
Proliferative responses of PBMC to C. jejuni antigen
Proliferative response to C. jejuni antigens of healthy donors, acute C. jejuni-induced GBS cases, ad acute GBS without
preceding C. jejuni infection (a), and patients with a history of Campylobacter enteritis-induced GBS, uncomplicated
Campylobacter enteritis, or Campylobacter-unrelated GBS (b). Incorporated 3H thymidine counts are means of triplicate
wells of stimulations with different bacterial strains.
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The phenotype of expanded T cells was determined in subsequent experiments by double-
immunofluorescent analysis with anti-CD3, anti-TCR αβ, and anti-TCR γδ monoclonal
antibodies, and compared to the phenotype of T cells at the onset of cell culture. Flow cytometric
analysis demonstrated extensive expansion of CD3+/TCRγδ+ T cells in the cultures of PBMC of
all healthy individuals tested. A representative example is shown in Figure 2. The eight C. jejuni
strains showed no differences in stimulatory capacity of γδ T cells.
In autoimmune and infectious diseases, an aberrant distribution pattern among TCR Vγ/Vδ
families and significant expansion or reduction of the entire γδ T cell population has been
reported. We therefore analyzed the frequency and Vγ/Vδ utilization of blood γδ T cells of GBS
patients and compared the results to those obtained from healthy individuals. In addition, we
performed a phenotypic analysis of blood γδ T cells with monoclonal antibodies against
molecules that provide information on their activation status, like HLA-DR, anatomical origin,
like CD8143, TCR-mediated signal transduction capacity, like TCRζ chain, CD3, and FcRIII144,
apoptosis related molecules (Fas/FasL)145, or killer cell inhibitory receptors (CD94)146. The results
show no statistically significant difference between the GBS and healthy control group (not
shown).
We next determined whether γδ T cells from C. jejuni non-responsive GBS patients were capable
of proliferating after stimulation with other antigens. To that end, PBMC of non-responder GBS
patients and healthy donors were incubated with a crude preparation of the γδ T cell antigen M.
tuberculosis147. Healthy donors as well as C. jejuni non-responsive GBS patients showed varying
γδ T cell responses to M. tuberculosis. The C. jejuni non-responder GBS patient group showed a
significantly diminished response (P = 0.044), albeit that some individual patients demonstrated
substantial γδ T cell proliferation after stimulation with M. tuberculosis (Figure 3). These
experiments suggest that lack of proliferative capacity is not an intrinsic property of the γδ T cells
in C. jejuni-related GBS patients. The diminished response in these patients to M. tuberculosis
may be explained by shared γδ T cell-stimulatory antigens.
Pan γδTCR
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1% 35%
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Pan γδTCR
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Figure 2
γδ T cell expansion after stimulation with C. jejuni
antigen
Percentages of γδ T cells of a healthy donor at day 0 and
day 12 after in vitro stimulation with C. jejuni antigen.
Cells are stained with anti-CD3-Cy5 and anti-γδ TCR-
FITC monoclonal antibodies and prior to flow
cytometric analysis. The percentages given are in the
living, CD3+ population.
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The basis for γδ T cell non-responsiveness was
further investigated by adding cytokines to the cell
cultures. γδ T cells have been shown to
constitutively express the high affinity IL-2
receptor and expand after stimulation with IL-
2112;113 or a combination of antigen and IL-2 or IL-
15131;148;149 PBMC of four non-responding GBS
patients were stimulated with C. jejuni, IL-2, IL-
15, or with C. jejuni antigen in combination with
these cytokines. After 12 days of culture,
expansion indices of γδ T cells were determined.
Figure 4 shows that γδ T cells from C. jejuni-
associated GBS patients do not respond to
stimulation with any of the single compounds, but
that stimulation with C. jejuni antigen in
combination with IL-2 or with IL-15 results in a
strong proliferation, comparable to that observed
with PBMC from normal donors.
It has been previously shown that in vitro stimulation of PBMC from M. tuberculosis infected
patients with M. tuberculosis antigen induces apoptosis of γδ T lymphocytes within 48 hours150. A
similar mechanism does not appear to be operative in cultures of cells derived from GBS patients
stimulated with C. jejuni antigen. Flow cytometric analysis of C. jejuni-stimulated cells at 24 hour
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Figure 3
γδ T cell expansion after stimulation with M.
tuberculosis and C. jejuni
Responsiveness of healthy subjects and C. jejuni
non-responsive GBS patients to M. tuberculosis.
The γδ T cell expansion index is plotted on the y-
axis.
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Figure 4
Restoration of the γδ Τ cell proliferative
response by cytokines
Response of healthy donors (open circles)
and Campylobacter non-responsive GBS
patients (each patient represented by a
different black symbol) to Campylobacter,
IL-2 or IL-15 alone, and Campylobacter
antigen in combination with IL-2 or IL-15.
The γδ T cell expansion index is plotted on
the y-axis.
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intervals unveiled that the percentage of γδ T cells within the CD3+ population remained
unaltered during the first 7 days in culture (results not shown).
Discussion
The most salient finding of this study is that γδ T cells in GBS patients with an antecedent acute
infection with C. jejuni fail to proliferate after in vitro stimulation with a crude antigen
preparation of this micro-organism. This is in striking contrast to the vigorous C. jejuni-induced
proliferative response of γδ T cells obtained from healthy individuals, individuals with C. jejuni-
related acute enteritis and GBS patients without evidence for an acute antecedent C. jejuni
infection. We observed that in some patients, γδ T cell non-responsiveness lasted for prolonged
periods of time after clinical recovery. In the most extreme case, the peripheral blood γδ T cells of
two patients that had recovered from C. jejuni-related GBS 7 years prior to the time of the
experiment, still completely failed to respond.
We did not detect quantitative or phenotypic differences in the blood γδ T cell population in GBS
patients and healthy controls that could explain the non-responsiveness. PBMC from GBS
patients contained normal numbers of circulating γδ T cells that, like γδ T cells in healthy
individuals, predominantly expressed TCR encoded by Vγ9/Vδ2 variable genes. Moreover,
expression levels of molecules related to γδ T cell activation status and TCR-mediated signal
transduction capacity (MHC class II, TCR ζ chain, γδ TCR, CD3, and FcγRIII), apoptosis related
molecules (Fas/FasL) or killer cell inhibitory receptors (CD94) were similar among γδ T cells of
GBS patients and healthy controls, confirming recently published data89. Although the γδ T cells
did not expand as a result of stimulation with C. jejuni antigen, we observed that they remained
present during the culture. The combined data distinguish GBS-related γδ T cell non-
responsiveness from M. tuberculosis related non-responsiveness where stimulation with M.
tuberculosis induces Fas/FasL-mediated γδ T cell death and disappearance of γδ T cells from cell
cultures150.
Several observations point to a possible mechanism of non-responsiveness. Four out of six C.
jejuni non-responder GBS patients also failed to respond to stimulation with preparations of M.
tuberculosis, a well-studied antigen inducing γδ T cell proliferation. Thus, non-responsiveness
does not appear to be restricted to a C. jejuni specific antigen but extends to a single or a category
of γδ T cell stimulatory antigens at least partially shared by M. tuberculosis and C. jejuni bacteria.
This hypothesis is further supported by the recent finding that γδ T cells display a diminished
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responsiveness in a non-selected (no discrimination between C. jejuni-related and non-related)
group of GBS patients to phosphoantigens, bacterial antigens that potently activate γδ T cells89.
Furthermore, T cells of GBS patients were found to produce little IL-2 upon polyclonal T cell
activation and showed impaired responses to IL-2151. We noted that γδ T cell responsiveness
could be completely restored by simultaneous stimulation of patients PBMC with C. jejuni and
the cytokines IL-2 or IL-15. Based on the combined data, we propose that the observed non-
responsiveness in GBS patients is not an inherent property of γδ T cells but rather reflect a
deficient cytokine production in the cell cultures, required to drive γδ T cell proliferation.
Several reports have shown that γδ T cells can alter antibody responses (reviewed by Born et
al.152). Transgenic mice lacking γδ T cells have an exacerbated autoimmune disease phenotype in
murine lupus153, and higher antibody titers against T cell-independent antigens of Borrelia
burgdorferi154 as compared to their littermates with functional γδ T cells. These results suggest
that γδ T cells may regulate potentially auto-aggressive immune responses. In GBS, antibodies
against C. jejuni have been shown to cross-react with peripheral nerve tissues. The concomitant
lack of cytokine production upon C. jejuni stimulation and ensuing γδ non-responsiveness may
result in deregulation of autoantibody production and disease. It is tempting to speculate that a
similar scenario, based on non-responsiveness of T cells after infection by micro-organisms,
unfolds during other autoimmune responses.
62
63
Chapter 6
Campylobacter DNA is present in circulating myelomonocytic cells of
healthy individuals and patients with Guillain-Barré syndrome
Ildiko Van Rhijn1, Nancy M. C. Bleumink-Pluym2, Jos P. M. Van Putten2, and Leonard H. Van
den Berg1
1Department of Neurology, University Medical Centre, Utrecht, The Netherlands, and
2Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht
University, Utrecht, The Netherlands
Accepted for publication in The Journal of Infectious Diseases
64
Abstract
Campylobacter jejuni is the prime cause of food-borne bacterial gastro-enteritis. An important
complication of C. jejuni enteritis is Guillain-Barré syndrome (GBS), an immune-mediated
disorder of the peripheral nerve. The presence of C. jejuni DNA in peripheral blood mononuclear
cells (PBMC) from GBS patients, C. jejuni enteritis patients, and healthy subjects was studied.
Two target genes, the flagellin and the ceuE gene, were used for PCR identification of
Campylobacter species in DNA extracted from PBMC. Approximately 30% of the healthy
individuals and 50% of the patients had PBMC containing C. jejuni DNA as verified by Southern
blot analysis or sequencing of the PCR products. Cell sorting revealed that Campylobacter DNA
was present in the CD14+ and CD33+ populations, indicating that cells from the myelomonocytic
lineage are the Campylobacter DNA carrying cells. These findings show that Campylobacter
DNA is present in blood cells from healthy human subjects, although viable bacteria could not be
demonstrated.
Introduction
Campylobacter jejuni is the leading cause of bacterial food-borne diarrheal disease throughout the
world. Campylobacter can penetrate and damage the intestinal mucosa leading to blood and
inflammatory cells in the stool155. However, also patients with mild diarrhea and asymptomatic
cases have been reported. Ongoing research focuses on possible bacterial virulence factors with as
milestone the completion of the whole genome sequence of Campylobacter.
An important complication of C. jejuni enteritis is Guillain-Barré syndrome (GBS), an acute
autoimmune inflammatory demyelinating polyneuropathy. Infection with C. jejuni has become
recognized as the most frequent antecedent pathogen for GBS95.
Several studies have shown that human monocytes derived from PBMC and monocytic cell lines
can phagocytose Campylobacter in vitro156. The presence of intracellular Campylobacter in
humans in vivo however, has not been reported. To investigate this possibility, we searched for
the presence of Campylobacter in PBMC of GBS patients, patients who had suffered from
uncomplicated C. jejuni enteritis, and healthy subjects.
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Material and Methods
Patients and control subjects
PBMC from 65 healthy blood bank donors, 10 patients with a history of uncomplicated culture-
proven Campylobacter enteritis, and 23 GBS patients, among which 11 patients with serological
evidence of a C. jejuni infection that preceded the development of GBS, were used in this study.
Acute phase serum of GBS patients was tested for the presence of anti-C. jejuni IgG, IgA, and
IgM in an ELISA as described91 and evaluated according to established criteria71. GBS was
diagnosed according to the criteria formulated by Asbury142.
Bacterial strains and culture
The C. jejuni strain 81116 and C. coli strain UA417 were grown (37°C, 22oC) on 5% lysed horse
blood-Columbia agar under microaerophilic conditions. For revitalization of Campylobacter, one
ml of PBS containing 5*106 of PCR-positive PBMC, or a series of 103 to 10-3 C. jejuni strain
81116, were injected into the yolk sac of seven-day-old embryonated eggs from specific-
pathogen-free (SPF) chickens as described157. After 48 h of incubation at 37°C, the vitellus fluid
was harvested and plated.
DNA isolation
PBMC were isolated from heparinized blood by Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden) density centrifugation. 106 cells were suspended QX1 buffer of a Qiaex II kit for DNA
extraction (Qiagen, Hilden, Germany), and sonicated in a bath sonicator for 3 minutes. DNA was
isolated according to the Qiaex protocol. To test the sensitivity of the PCR reactions, heat-killed
bacteria (10 min, 100oC) were titrated in a PCR-negative PBMC sample prior to DNA isolation.
PCR conditions
For the amplification of the flagellin A and B intergenic sequences, semi-nested primersets were
used as described158. For the PCR of the ceuE gene different semi-nested primersets were used,
specific for the C. jejuni or the C. coli ceuE gene. In addition to the primers described by
Gonzalez159, we designed two 5'-located primers to obtain two semi-nested primersets (COL0: 5'-
CCC TGT AAG TCA GAT TGA TGC CC-3', JEJ0: 5'-CGT AAG TCA AAT TAA TGG TAA-
3'). Cycling conditions were as described, with minor modifications.
DNA sequencing
PCR products were cloned into the pGEM-T Vector (Promega, Madison, WI) and transformed
into E. coli. Randomly-picked bacterial colonies were used for plasmid isolations and nucleotide
sequence analysis. The T7 promoter primer was used for sequencing with the Terminator Ready
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Reaction DyeDeoxy Cycle Sequencing Kit (Perkin-Elmer Applied Biosystems, Foster City, CA).
Samples were analyzed by automated fluorescence detection.
Southern blotting
Second round ceuE PCR products were blotted onto Nitrocellulose membrane (Bio-Rad,
Hercules, CA) by overnight capillary blotting. Sequenced C. coli or C. jejuni ceuE PCR products
were 32P-labeled (RadPrime DNA labeling system, Life Technologies, Breda, Netherlands) and
used as a probe. The hybridization procedure was performed at 42°C and was followed by three
washes in 0.1% SDS/0.2*SSC, at 58ºC. Hybridization patterns were visualized by conventional
autoradiography on films.
Cell sorting
All antibodies were obtained from Becton Dickinson (San Jose, CA). CD14+, CD19+, CD33+, and
CD3+ populations were sorted from PBMC on a FACStar plus cell sorter. Purity of the cell
populations after sorting was always 98% or higher. 3000 Cells were sorted and DNA was
isolated as described.
Statistical analysis
SPSS 8.0 for Windows was used for statistical analysis. Chi-square tests with continuity
correction (Yates' corrected chi-square) was used. If numbers smaller than 5 occurred, Fisher's
Exact test was used.
Results
Evaluation of methods
Two target genes (fla and ceuE) were used for PCR identification of Campylobacter. A PCR on
the intergenic sequence of the flagellin A and B genes was chosen for its reported high
sensitivity158. This PCR amplifies flagellin fragments from C. jejuni and C. coli, but not from
other Campylobacter species or other bacterial genera. Amplification of this region yielded a
single band of the expected size of approximately 200 bp (not shown). Sequencing confirmed that
the obtained PCR product consisted of Campylobacter flagellin intergenic sequence. Because
considerable variability in the flagellin intergenic region has been reported158, we considered
Southern blotting unsuitable to increase the sensitivity of the detection.
The PCR on the ceuE gene, encoding a siderophore-binding protein involved in iron acquisition,
does discriminate between C. jejuni and C. coli159. CeuE was detected in the samples by a
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combination of PCR and Southern blotting. Using sequenced ceuE fragments as probes, we
confirmed that there was no cross-reactivity between the two Campylobacter species (Figure 1A).
For both the flagellin PCR and the ceuE PCR/Southern blotting procedure the sensitivity of
detection was determined at about 10 C. jejuni or 10 C. coli in 25,000 PBMC. Controls without
template DNA that were used in each PCR analysis were always negative. In order to exclude
contamination from the environment as a source of positive PCR results, we performed several
experiments in a lab where experiments with Campylobacter or Campylobacter-derived DNA had
never been performed. Of the 27 blood samples of healthy donors that were processed under these
circumstances, 6 were flagellin positive, demonstrating that contamination is unlikely to account
for the observed results.
Screening of human PBMC for the presence of Campylobacter DNA
The distribution of ceuE and flagellin positive samples in the different groups of donors is
summarized in Table 1. The ceuE PCR/Southern blotting procedure revealed that a considerable
number of the samples was positive for C. jejuni, while a few samples tested positive for C. coli
(Figure 1B). Three subjects were positive for both species. Sequencing of 32 cloned flagellin PCR
Figure 1
CeuE Southern blotting
A  To demonstrate the specificity of the PCR/Southern blot procedure, we performed a PCR with primers specific for the
C. jejuni or the C. coli ceuE gene on DNA isolated from a C. jejuni and a C. coli strain. This material was blotted and
detected with sequenced C. jejuni and C. coli ceuE probes. Only when the input DNA, PCR primerset, and probe were
from the same species, a strong signal of the correct size was detected (lane 2 and 7). Weak cross-reactivity was observed
when C. jejuni DNA was amplified with C. jejuni specific primers and detected with the C. coli probe and vice versa
(lane 3 and 6), a procedure not relevant for the experimental samples. C. jejuni DNA did not produce any signal when
amplified with C. coli ceuE primers and detected with C. coli probe and vice versa (lane 1 and 8), demonstrating that our
experimental set up led to highly specific results.
C. jejuni (B) and C. coli (C) specific PCR/Southern blot procedures performed on a positive control sample with DNA
containing the equivalent of 25,000 PBMC and 10 C. jejuni or 10 C. coli (lanes 1) and on experimental samples
containing the equivalent of 25,000 PBMC of 23 different healthy donors (lanes 2 – 24).
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products yielded sequences which all scored as Campylobacter-derived in a BLAST search of the
database available at www.ncbi.nlm.nih.gov/BLAST/.
In an attempt to characterize the Campylobacter DNA carrying cells, we sorted 3000 CD14+,
CD19+, CD33+, and CD3+ cells from PCR-positive PBMC and performed flagellin PCR on the
samples. Only the CD14+ and CD33+ positive populations were flagellin positive. This indicates
that the Campylobacter DNA was present in monocytes and, possibly, myeloid dendritic cells.
Persistence of Campylobacter
From five study subjects (three fla positive and two negative individuals) we were able to obtain a
second blood sample one year or more after the first sample. PCR on the follow-up samples
yielded identical results as found for the initial samples. The probability that this is accidentally is
0.013, suggesting that the presence or absence of Campylobacter DNA in the blood of a certain
person is a stable characteristic on a 1-2 year time scale.
As the fla intergenic region is variable among C. jejuni strains158, identical DNA sequence at
different time points may indicate that certain Campylobacter DNA persists in the PBMC. The fla
sequences obtained from the samples could be classified into three groups with only minimal
variations within each group. Comparison of fla sequences obtained at different time points
showed that initial and follow-up sequences always contained sequences of the same group, with
only minimal differences between the first and second sample. In one case, 4 single base
deviations from the group consensus sequence were again found in the follow-up sample,
suggesting that the same Campylobacter DNA was being amplified.
   Flagellin C. jej  CeuE C. coli CeuE
pos. neg. pos. neg. pos. neg.
GBS patients
       Preceding C. jejuni  infection (n = 11) 6 5 6 5 0 11
       No preceding C. jejuni  infection (n = 12) 5 7 6 6 0 12
C. jejuni  enteritis (n = 10) 4 6 6 4 1* 9
Healthy donors (n = 65) 22 43 21 44 4** 61
* This patient was also positive for C. jej  CeuE 
** Two of these donors were also positive for C. jej  CeuE
Table 1             Numbers of fla and ceuE positive samples
Table 1
Numbers of fla and ceuE positive samples
The number of positive and negative samples in the different groups of subjects is shown. The results of the fla PCR and the C.
jejuni or C. coli specific ceuE PCR/Southern blot are shown separately. None of the patient groups differed significantly (P <
0.05, Fisher's Exact test) from the group of healthy donors in the fla  or the ceuE results. Only if the group of C. jejuni enteritis
patients and the group of Guillain-Barré syndrome (GBS) patients with preceding C. jejuni infection were combined, this led to
significant differences (P < 0.05, Chi-square tests) in the frequency of C. jejuni positivity as determined with the C. jejuni-specific
ceuE PCR/Southern blot.
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Culturability of Campylobacter from PBMC
Direct plating of 3*106 PCR positive PBMC before or after lysis in 1% saponin did not yield
detectable growth of bacterial colonies. In vitro studies have shown that C. jejuni ingested by
human macrophages convert to a coccal form156. These coccoid bacteria may be viable but not
culturable by direct plating. Culturable C. jejuni has been recovered successfully from this state
by inoculation in the yolk sacs of embryonated chicken eggs157. We applied this method to human
PCR-positive PBMC derived from three different subjects. No Campylobacter were recovered,
although the viability of a series of 103 to 10-3 log phase-grown C. jejuni was increased by 2 logs
by this procedure.
Discussion
This study shows that circulating human PBMC contain Campylobacter DNA. Within the limits
of the sensitivity of our assay, approximately 30% of all healthy individuals is positive, based on
the detection of two independent Campylobacter genes by PCR, and confirmed by sequencing
and Southern blotting. To our knowledge there are no previous reports of intracellular
Campylobacter DNA in freshly isolated human cells. For GBS and enteritis patients, higher
percentages of positive samples were found than for healthy blood donors, but the differences
were smaller than might have been expected, and were not statistically significant. The high
percentage of Campylobacter DNA positive blood donors implies that a large part of the
population has a history of, perhaps non-symptomatic, Campylobacter infection or still carries the
bacteria in an unidentified niche. The latter may also explain the presence of anti-Campylobacter
IgG in the serum of a high percentage of the healthy population91.
We have several possible explanations for the frequent presence of C. jejuni DNA in human
myelomonocytic cells. One is that there may be a continuous supply of C. jejuni from the food or
from an intestinal reservoir to these cells, which may efficiently engulf and destroy the bacteria.
In this concept, an ongoing, subclinical gastro-intestinal infection with bacterial translocation of
the intestinal mucosa and influx of Campylobacter into the bloodstream has to be assumed, which
is unlikely.
An alternative scenario is that the ingested Campylobacter are killed, but that their DNA is
resistant to degradation and persists within the cells. This phenomenon has been described for
Chlamydia pneumoniae160 and for several bacterial species that are found in the joints of patients
with arthritis161. The inability to recover Campylobacter from PBMC is consistent with this
hypothesis. However, in this scenario the apparent persistence of the DNA far beyond the normal
life-time of the host cells remains unexplained.
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A third possible explanation for our results is that during a Campylobacter infection, bacteria are
ingested by the myelomonocytic cells and persist in the cells in a viable but not culturable form
and without causing clinical symptoms. Campylobacter has several features that point towards a
facultative intracellular life-style including a catalase and a superoxide dismutase gene that
protect against oxidative killing162;163. A natural intracellular niche has not yet been described, but
our data suggest human myelomonocytic cells as a likely candidate. But again, the observed long
term persistence of the DNA seems incompatible with the limited life span of the cells, unless it is
assumed that the viable bacteria are able to expand the life span of the host cells. This
phenomenon has been described for Mycobacterium bovis (BCG) and Brucella suis. These
bacteria increase the half-life of host monocytes by suppressing apoptosis probably via an active
process164;165. Despite extensive effort, we were unable to recover viable Campylobacter from
PBMC. However, the presence of a viable, non-culturable Campylobacter that are capable to
influence the life span of the host cells, cannot be excluded.
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Chapter 7
General discussion
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Why a general discussion?
A general discussion is meant to add something to the discussions at the end of each Chapter The
value of the thesis in its entirety has to be discussed, whether the goals have been properly
addressed and attained, and what it adds to the field of interest. A disadvantage of the current
practice to present experimental Chapters as independent papers is that certain issues that may
have value for the project as a whole are not or only superficially mentioned in the Chapters
because they did not fit in the narrow scope of a paper. Consequently, relevant aspects that were
underexposed in the experimental Chapters are emphasized here.
The general discussion is not submitted for publication in a peer-reviewed journal, while the
Chapters are. Therefore, critical review and speculations in the general discussion may reach a
little further than in the Chapters.
Experimental approach
The goal of this thesis was to unravel how activation of the immune system causes inflammatory
neuropathy, with particular focus on the role of T lymphocytes. In general, it is a difficult to prove
theories concerning pathogenesis of human disease. In principle, the experimental approach
entails the collection of supportive data from in vitro experiments with human material and the
design and execution of experiments in mouse models of the disease under consideration. Also,
prospective longitudinal studies are suitable for the evaluation of factors involved in
pathogenensis if the studied disease has a sufficiently high incidence, which is not the case for
inflammatory neuropathies. This thesis was however not meant to study risk factors for
inflammatory neuropathies. My intention was to mechanistically describe the sequence of
immunological events that lead to damage of the peripheral nervous system. This approach is
most valuable if pathological and normal immune reactions are studied, and clear differences are
found that support or reject the working hypothesis.
The search for a plausible theory on how T cells contribute to the development of inflammatory
neuropathy was approached in different ways. Nerve tissue from patients suffering from
peripheral neuropathy was studied to define the status of antigen presentation and T cell
stimulatory molecules in situ using immunohistochemistry. Blood from patients was tested for T
cell reactivity against peripheral nerve constituents. Alternative approaches were based on the
observation that GBS is often preceded by an infection with C. jejuni. The in vitro T cell response
against this pathogen was studied in experiments with PBMC and C. jejuni antigen. Molecular
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biological techniques like PCR, Southern blotting, and sequencing, were used to detect
Campylobacter DNA in blood cells from healthy donors and patients.
Observations and ensuing hypothesis
Chapter 2
In nerve biopsy material of inflammatory neuropathy patients, cell surface molecules were present
that could play a role in activating primed T cells166, but no support was found for the hypothesis
that naive autoreactive T cells are locally activated to cause tissue damage. In a study from
Bosboom et al.3, the phenotype of the T cells that infiltrate the nervous tissue was described, and
compared with that of blood. Many different T cell receptor (TCR) Vβ chains were expressed,
and αβ TCR+, γδ TCR+, CD4+, and CD8+ T cells were all present. Collectively, these data argue
against the presence in nerve tissue of an oligoclonal T cell population, or a T cell population that
expresses another marker that points to a common basis of antigen recognition, like a mainly CD4
or CD8-positive T cell population, that accounts for the studied peripheral neuropathies. GBS-
derived material was not used for these studies because biopsies for diagnostic purposes are not
taken nowadays, and no cryopreserved old material was available. In publications that do describe
GBS-derived material1, the same overall picture was provided of a T cell population infiltrating
affected nerve that does not differ from an average circulating T cell population.
These observations are therefore profoundly different from those found in some other organ-
specific autoimmune diseases. For example, in polymyositis the phenotype of the infiltrating T
cell population in affected muscle, the skewed or even uniform Vβ expression, and antigen
presentation, collectively suggest that local damage is caused by Class I presentation to CD8+ T
cells expressing a single or restricted set of Vβgenes167-169. Class I expression in muscle cells has
been shown to be a hallmark in the development of myositis170.
A possible scenario for the origin and perpetuation of peripheral neuropathies is that local nerve
tissue damage is not primarily or directly caused by T cells, but by cytokines, antibodies and/or
activated macrophages. T cells may play a role in the stimulation of antibody production and in
the production of cytokines, but the localization of these processes is most likely not in the
peripheral nerves, but for example in the lymphoid organs.
Chapter 3
In an attempt to gain insight into the reactivity of circulating T cells to peripheral nerve
constituents, lipid extractions and protein fractions of normal PNS myelin, and crude homogenate
of CIDP-affected peripheral nerve were used to stimulate ex vivo PBMC of GBS and CIDP
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patients, and healthy controls. Although a strong memory T cell response against tetanus toxoid
(TT) could be measured in all patients, no response against any of the antigen preparations of
PNS myelin could be demonstrated. Because TT is widely accepted as the standard protein recall
antigen that stimulates memory CD4+ cells, I conclude in this Chapter that there is no similar
memory response against myelin proteins in patients or healthy controls.
Although it may undermine the conlusions of Chapter 3, some comments on the use of TT as a
recal antigen are warranted. TT is a formaldehyde-treated form of tetanus toxin, which has
inherent immunostimulatory qualities that point to innate stimulatory activities171;172 in addition to
the adaptive memory T cell response that it elicits. This general immunostimulatory property or
adjuvant-like activity may be circumvented by using the synthetic TT peptide p2, containg amino
acids 830 – 844 of TT, that has been shown to universally bind HLA-DR, and towards which the
immunodominant memory T cell response is directed. However, even the in vitro T cell response
to this peptide is probably not comparable to the response against other recall protein antigens
because 1) it can associate with all known HLA-DR alleles173, leading to a high percentage of DR
molecules occupied by the peptide, 2) synthetic peptides can bind directly to class II MHC
molecules, circumventing the natural processing route in the antigen presenting cells174, which
renders the peptide usuitable as control for the antigen presenting capacities of the in vitro system
for which is serves as a control, 3) peptide interaction with class II MHC generates epitopes
dissimilar to those resulting from intracellular processing175, and 4) because the half-life of the
peptide in human serum is approximately 10 minutes176;177, which is much lower than what is
found for most proteins, it is expected that the kinetics of both types of differs considerably.
Optimally, in experiments concerning T cell memory, a negative responder population like adults
that have not been vaccinated against tetanus should be used in order to exclude T cell responses
that are not due to a real recall response.
It is even harder to conceive a proper positive control antigen for a MHC class I-restricted recall
response in vitro using the experimental set up we used with PBMC as responder population.
Taken together, this difficulty in finding proper positive and negative controls is a reason to
reconsider the feasibility of primary, in vitro T cell stimulations.
Chapter 4
Because many patients with GBS have suffered from a preceding C. jejuni infection, the in vitro
T cell response against this micro-organism was studied. The results of these studies were
described in Chapters 4 – 6. The in vitro T cell response of healthy donors against C. jejuni was
investigated in Chapter 4 and it was found that γδ T cells specifically expand upon such a
stimulation. A phosphoantigen is the active compound, and the activation of the γδ T cells
75
depends on the presence of CD4+ αβ T cells or the addition of IL2 or IL15 during culture.
Expansion of γδ T cells has been observed by others when T cells were stimulated in vitro with
certain bacteria or bacterial antigens, suggesting an important role for these cells in anti-bacterial
immunity. However, human γδ T cells have also been shown to be able to kill uninfected human
target cells, and they have also been implicated in anti-viral immunity. This multifunctional
character of γδ T cells makes it difficult to speculate about their role in the induction of
autoimmunity. It is important to note that other T cell populations expressing αβ TCR may still be
involved in the response against C. jejuni, but that they go undetected because of the vigorous γδ
T cell proliferation.
Chapter 5
Experiments with T cells of GBS patients pointed to aberrant reactivity towards Campylobacter
as compared to healthy individuals. The γδ Τ cells of acute GBS patients with antecedent C. jejuni
infections completely failed to respond to in vitro Campylobacter stimulation. Insufficient
cytokine production by CD4+, αβ T cells was proposed as an explanation for the observed lack of
responsiveness, because these cells appeared to be indispensable for a normal the vigorous T cell
response in healthy donors. The addition of low amounts of IL2 or IL15 to cultures of non-
responding γδ T cells cultures rendered them responsive. Further support for an impaired cytokine
production in GBS patients comes from the finding that polyclonally-acivated T cells from
patients in vitro produce low quantaties of IL2151.
In apparent contrast, GBS patients have been shown to harbor high titers of circulating IL2 and
soluble IL2-receptors compared to healthy controls. Therefore the possibility of a higher
cytokine-response threshold of the γδ T cells of non-responsive GBS patients instead of a lower
cytokine production by the αβ T cells should be taken into account. Alternatively, it is
conceivable that an IL2-ELISA does not distinguish between IL2 bound to the soluble IL2R or
free IL2178, and since sIL2R is present in serum of GBS patients, it is conceivable that there is no
free IL2 in GBS serum.
γδ T cell non-responsiveness was not found in Campylobacter enteritis patients that did not
develop GBS, showing that that this phenomenon may be involved in the pathogenesis of GBS.
However, since γδ T cells are innate lymphocytes, involved in the rapid ‘defense’ against micro-
organisms, an alternative hypothesis is that defective γδ T cell reactivity leads to more severe
infection with stronger activation of the adaptive B and T cell mediated immunity and thus to
GBS. This hypothesis is based on the assumption that γδ T cell non-responsiveness exists before
infection with C. jejuni or develops at the onset and as a consequence of infection. The fact that
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all acute Campylobacter-induced GBS patients are non-responders, and only part of the recovered
Campylobacter-induced GBS patients are non-responders, and some are low-responders suggests
that non-responsiveness develops at the time of GBS, and slowly subsides. This argues against the
idea that GBS patients had a pre-existing slow and inefficient innate defense against
Campylobacter which lead to a more severe infection and stronger adaptive B and T cell
response. But it still leaves open whether γδ T cell non-responsiveness is caused by the
Campylobacter infection and causes GBS, or whether it is a side effect of GBS. An attractive
hypothesis is that T cell non-responsiveness leads to defective immune regulation and
autoimmune disease.
Chapter 6
The idea that the severity, duration, or localization of the C. jejuni infection may influence
whether or not a C. jejuni enteritis leads to T cell non-responsiveness, and is followed by GBS led
to the experiments described in Chapter 6. The only aspect of prior Campylobacter exposure that
was studied was whether or not Campylobacter DNA was still present in PBMC of the studied
subjects. This led to the remarkable observation that 30% of the healthy donors carry
Campylobacter DNA in their monocytes. Of the GBS patients and Campylobacter enteritis
patients that were studied, 50% was positive. Though the work is by no means a comprehensive
description of the history of the Campylobacter infection that an individual has experienced, these
experiments suggest that the persistent presence of Campylobacter DNA and presumably antigen
in antigen presenting cells of a large proportion of the human population does not render the T
cells of these individuals unresponsive to in vitro Campylobacter stimulation.
Integration in existing hypothesis on pathogenesis of peripheral neuropathies
Usually, a hypothesis on the pathogenesis of a disease is based on a combination of
environmental and host factors. Even descriptions of the molecular mimicry hypothesis of GBS
and searches for the 'bad bug', both emphasizing environmental factors in the development of
GBS, take host factors into account. Host factors that have been studied are restricted to
straightforward genetic factors like cytokine and cytokine receptor genes and HLA- and FcR
polymorphisms. The work described in this thesis may not be sufficiently worked out to add a
fully-developed hypothesis to this field, but some novel ideas with potential importance, mainly
concerning the status of the immune system of the host are presented.
A hypothesis on the sequence of events leading to GBS, combining established ideas with the
findings presented in this thesis may be formulated as follows. An infection with a ganglioside-
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mimicking pathogen is the first, initiating event in the development of GBS. This may be a
Campylobacter infection, or other GBS-associated pathogens that have been shown to elicit anti-
ganglioside antibodies179. It is also conceivable that other cross-reactive epitopes play a role.
Initially, a normal immune response will develop which consists of a bactericidal or cytotoxic
innate lymphocyte response, followed by an adaptive T cell response, and antibody production.
For as yet unknown reasons a subset of T cells becomes hyperactivated followed by anergy180 or a
certain T cell population was already non-responsive to stimulation with antigen before the actual
infection took place. If these nonresponsive T cells are the ones that should normally support
regulatory T cells, or should perform a regulatory function themselves, a physiological immune
response now turns into a pathogenic one, characterized by a long duration and heightened
intensity. As a consequence, pathogenic autoantibodies and immune-stimulatory molecules are
produced in high amounts and gain access to the peripheral nerve where complement and
macrophage activation damage the nerve tissues. In this scenario, molecular mimicry alone is not
sufficient to cause autoimmunity, but it is a condition for a pathogenic response. Only the
combination of defective downregulation and a peripheral nerve-mimicking epitope on a
pathogen may lead to GBS.
The question that arises immediately is why T cells become non-responsive. Potential answers to
this question are: 1) the infection is very severe due to an inherent property of the pathogen, or 2)
due to an inadequate early defense of the host, both leading to hyperactivation and anergy, or 3)
genetic host factors, or 4) other immunological host factors contribute to the observed T cell non-
responsiveness. It may for example be crucial how the host immune system was primed before
the GBS-inducing infection was established. Most of the suggestions for additional studies that
will follow below address these issues.
Because this thesis was meant to encompass not only GBS, but also CIDP as a model
autoimmune peripheral neuropathy, I will make some comments about CIDP as well. The results
from Chapter 2, suggesting that T cells are probably not locally causing primary damage, and
from Chapter 3, that a classical in vitro CD4 memory T cell response against myelin is not found
in CIDP patients, both point to the limitations of current techniques and ideas that are used to
address this issue. New technical and theoretical approaches may include a closer look at T-
independent B cell activation or the role of innate immunity in this disease. Also research in the
field of regulatory immune responses that may prevent tissue damage may prove useful.
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Suggestions for additional studies
In order to develop the aforementioned hypothesis concerning immune regulation in the
pathogenesis of GBS, new experimental data should be collected.
The role of γδ T cells in the pathogenesis of GBS may be studied in γδ T cell knock out mice.
Although the antigen reactivity of human and mouse γδ T cells widely differ, there may be a
functional overlap. γδ T cell knock out mice may be infected with with Campylobacter and
monitored for the development of GBS-associated features like clinical signs of weakness,
demyelination, and higher antibody titers against Campylobacter than wild type mice.
The question arises whether the idea of hyperactivation of T cells followed by non-responsiveness
is also applicable to other infections that are associated with GBS. In vitro T cell stimulation of
healthy donors and GBS patients for with GBS-associated pathogens should shed light on this
issue.
A final question that should be addressed in this thesis concerns the potential benefits that patients
may ever have from this work. If the ideas concerning defective immune regulation hold, the
question rises how this could contribute to the cure or prevention of GBS. Prevention is only a
realistic option if a disease has a high incidence and mortality. Interventions in an ongoing
immune response are notoriously difficult. However, the design of therapeutic strategies greatly
benefits form a thorough understanding of the pathogenesis of the disease. In addition, an animal
model that mimicks both the clinical characteristics and pathogenesis of the disease is urgently
needed for the development of novel therapies.
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Summary
This thesis deals with three subjects: inflammatory neuropathies, the (human) immune system,
and microbial pathogens. The work is mainly focussed on Guillain-Barré syndrome (GBS), an
acute inflammatory neuropathy that is often induced by a bacterium called Campylobacter jejuni,
and chronic inflammatory demyelinating polyneuropathy (CIDP). In the broadest sense, the goal
is to reveil how activation of the immune system causes inflammatory neuropathy. Much less is
known about the T cell response than about the antibody response in inflammatory neuropathy
and therefore the thesis is entirely focussed on T cells. The T cell response to myelin and to the
microbial pathogen C. jejuni, and the status of the T cells during inflammatory neuropathy are
described. The newly obtained data will be put together into a hypothesis on the pathogenesis of
GBS.
The presence of adhesion-, costimulatory-, and antigen presenting molecules on different cell
types as conditions for local T cell activation in human sural nerve biopsies of CIDP and
vasculitic neuropathy patients and healthy controls is described in Chapter 2. In biopsies from
CIDP and vasculitic neuropathy patients, but not healthy controls, Schwann cells expressed the
adhesion/T cell stimulatory molecule CD58 (LFA-3). Expression of the co-stimulatory molecule
CD86 was detected on vascular tissue in patients with vasculitic neuropathy. Schwann cells of a
single vasculitis patient strongly expressed CD1b, a molecule involved in the presentation of self
glycolipids to T cells. There was no evidence for the presence of dendritic cells in sural nerve
biopsies. These findings suggest that T cell activation can be perpetuated locally nerves of
patients with CIDP and vasculitic neuropathy, but no support was found for the hypothesis that
naive autoreactive T cells are locally activated to cause tissue damage.
In an attempt to gain insight into the reactivity of circulating T cells to peripheral nerve
constituents, lipid extractions and protein fractions of normal peripheral nervous system myelin,
and crude homogenate of CIDP-affected peripheral nerve were used to stimulate ex vivo T cells of
GBS and CIDP patients and healthy controls. As described in Chapter 3, a strong memory T cell
response against tetanus toxoid could be measured in all patients, but no response against any of
the preparations of myelin could be demonstrated.
Because many patients with GBS have suffered from a preceding C. jejuni infection, the in vitro
T cell response of healthy donors against this micro-organism was described in Chapter 4. We
found a preferential expansion of peripheral blood γδ T cells after exposure to crude sonicates of
C. jejuni. Expansion of γδ T cells was dependent on the presence of CD4+/+ T cells in the
cultures or addition of exogenous IL-2 or IL-15. C. jejuni stimulation was mediated via the T cell
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receptor and appeared to be induced by a non-proteinaceous bacterial antigen, most likely of
phosphoantigenic origin.
In contrast, γδ Τ cells of acute GBS patients with antecedent C. jejuni infections completely failed
to respond, as described in Chapter 5. GBS patients without evidence for antecedent C. jejuni
infections and individuals with C. jejuni enteritis without GBS responded like healthy individuals.
In some patients, the γδ Τ cell non-responsiveness could last for years after recovery from GBS.
Supplementing cell cultures with the cytokines IL-2 or IL-15 resulted in restoration of the
γδ Τ cell proliferative response, suggesting that γδ T cell non-responsiveness in GBS patients
reflects a lack of production of cytokines required to activate γδ T cells. T cell non-responsiveness
and ensuing defective autoimmune regulation may be a more general mechanism leading to
autoimmune disease.
In Chapter 6 the presence of C. jejuni DNA in blood mononuclear cells from GBS patients, C.
jejuni enteritis patients, and healthy subjects was studied. Because persistent antigen can cause T
cell non-responsiveness, the presence of C. jejuni in GBS patients may provide an explanation for
the observed T cell non-responsiveness in these patients. Two target genes, the flagellin and the
ceuE gene, were used for PCR identification of Campylobacter species. DNA extracted from
blood mononuclear cells of approximately 30% of the healthy individuals and 50% of the patients
contained C. jejuni DNA as verified by Southern blot analysis or sequencing of the PCR products.
Cell sorting revealed that Campylobacter DNA was present in the CD14+ and CD33+
populations, indicating that cells from the myelomonocytic lineage are the Campylobacter DNA
carrying cells. These data did not provide us with an explanation for the T cell non-
responsiveness in GBS patients as observed in Chapter 5.
A hypothesis on the sequence of events leading to GBS, combining established ideas with the
findings presented in this thesis may be formulated as follows. An infection with a ganglioside-
mimicking pathogen is the first event in the development of GBS. Initially, a normal immune
response will develop which consists of a bactericidal or cytotoxic innate lymphocyte response,
followed by an adaptive T cell response, and antibody production. For as yet unknown reasons a
subset of T cells becomes hyperactivated followed by anergy or a certain T cell population was
already non-responsive to stimulation with antigen before the actual infection took place. If these
nonresponsive T cells are the ones that should normally support regulatory T cells, or should
perform a regulatory function themselves, a physiological immune response now turns into a
pathogenic one, characterized by a long duration and heightened intensity. As a consequence,
pathogenic autoantibodies and immune-stimulatory molecules are produced in high amounts and
gain access to the peripheral nerve where complement and macrophage activation damage the
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nerve tissues. In this scenario, molecular mimicry alone is not sufficient to cause autoimmunity,
but it is a condition for a pathogenic response. Only the combination of defective downregulation
and a peripheral nerve-mimicking epitope on a pathogen may lead to GBS.
The question that arises immediately is why T cells become non-responsive. Potential answers to
this question are: 1) the infection is very severe due to an inherent property of the pathogen, or 2)
due to an inadequate early defense of the host, both leading to hyperactivation and anergy, or 3)
genetic host factors, or 4) other immunological host factors contribute to the observed T cell non-
responsiveness. It may for example be crucial how the host immune system was primed before
the GBS-inducing infection was established.
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Samenvatting
In dit proefschrift worden drie onderwerpen behandeld: inflammatoire neuropathieën, het
menselijke immuunsysteem, en ziekteverwekkende bacteriën. Het werk gaat voornamelijk over
Guillain-Barré syndroom (GBS), een acute inflammatoire neuropathie die vaak door de bacterie
Campylobacter jejuni veroorzaakt wordt, en chronische inflammatoire demyeliniserende
polyneuropathie (CIDP). Het doel in brede zin is erachter te komen hoe activatie van het
immuunsysteem een inflammatoire neuropathie veroorzaakt. Aangezien er veel minder bekend is
over de T cel respons dan over de antilichaamrespons in inflammatoire neuropathieën is dit
proefschrift geheel gericht op de T cel respons. De T cel respons tegen myeline en C. jejuni en de
status van de T cellen gedurende inflammatoire neuropathie worden beschreven. De nieuwe
gegevens zullen in een hypothese over de pathogenese van GBS worden verwerkt.
De aanwezigheid van adhesie-, costimulatie-, en antigeenpresenterende moleculen die plaatselijk
in nervus suralis biopten van patiënten met CIDP en vasculitisneuropathie en gezonde controles T
cellen zouden kunnen activeren is beschreven in Hoofdstuk 2.
In de biopten van CIDP en vasculitisneuropathie patiënten, maar niet in die van gezonde
controles, brachten de Schwanncellen het adhesie-/T cel stimulatiemolecuul CD58 (LFA-3) tot
expressie. Het co-stimulatiemolecuul CD86 kwam tot expressie in vaatweefsel van
vasculitisneuropathie patiënten. De Schwanncellen van een vasculitisneuropathie patiënt brachten
CD1b, een molecuul dat bij de presentatie van glycolipiden afkomstig uit het eigen lichaam
betrokken is, sterk tot expressie. Er waren geen aanwijzingen voor de aanwezigheid van
dendritische cellen in nervus suralis biopten. Deze bevindingen suggereren dat T cel activatie in
stand gehouden kan worden in zenuwen van CIDP en vasculitisneuropathie patiënten, maar er
waren geen aanwijzingen dat naïeve, autoreactieve T cellen plaatselijk geactiveerd kunnen
worden en weefselschade kunnen aanrichten.
Om inzicht te krijgen in de reactiviteit van circulerende T cellen tegen componenten van perifere
zenuw werden vetextracten en eiwit fracties van normaal myeline uit de perifere zenuw, en ruw
homogenaat van door CIDP aangedane zenuw, gebruikt om ex vivo T cellen van CIDP en GBS
patiënten en gezonde controles te stimuleren. Zoals in Hoofdstuk 3 beschreven is kon in alle
patiënten een sterke secundaire respons door T cellen tegen tetanus toxoïde gemeten worden,
maar tegen geen enkel myeline preparaat.
Omdat veel GBS patiënten aan een voorafgaande infectie met C. jejuni hebben geleden is de in
vitro T cel respons van gezonde donoren tegen deze bacterie beschreven in Hoofdstuk 4. Er werd
een expansie van uitsluitend γδ T cellen gevonden na blootstelling aan een ruw sonicaat van C.
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jejuni. De expansie was afhankelijk van de aanwezigheid van CD4+/+ T cellen in de kweek of
toevoeging van exogeen IL-2 of IL-15. Stimulatie door C. jejuni vond plaats via de T cel receptor
en bleek geïnduceerd te zijn door een bacterieel antigeen dat geen eiwit is maar waarschijnlijk een
fosfoantigeen.
γδ T cellen van acute GBS patiënten met voorafgaande C. jejuni infectie reageerden helemaal
niet, wat beschreven is in Hoofdstuk 5. GBS patiënten zonder voorafgaande C. jejuni infectie en
patiënten met een C. jejuni infectie zonder GBS reageerden als gezonde donoren. In sommige
patiënten duurde de γδ T cel inactivatie jaren nadat ze hersteld waren van GBS. Als de cytokines
IL-2 of IL-15 werden toegevoegd aan de kweken resulteerde dit in herstel van de proliferatieve
respons van γδ T cellen, wat suggereert dat de inactivatie in GBS patiënten te wijten is aan een
tekort aan cytokineproduktie die nodig is om de γδ T cellen te activeren. T cel inactivatie en
daaruit voortvloeiende defecte immuunregulatie zou een algemeen principe kunnen zijn dat tot
auto-immuniteit kan leiden.
In Hoofdstuk 6 wordt de aanwezigheid van C. jejuni DNA in witte bloedcellen van GBS
patiënten en gezonde personen bestudeerd. Omdat continu aanwezig antigeen tot T cel inactivatie
kan leiden zou de aanwezigheid van C. jejuni in GBS patiënten een verklaring kunnen geven voor
de T cel inactivatie in GBS patiënten. Twee genen, het flagelline gen en het CeuE gen, werden
gebruikt voor PCR identificatie van Campylobacter soorten. Het DNA geïsoleerd uit witte
bloedcellen van ongeveer 30% van de gezonde donoren en 50% van de patiënten bevatte C. jejuni
DNA, en dat was geverifieerd met Southern blot analyse of sequentiebepaling van het PCR
product. Het bleek dat cellen die gesorteerd waren op CD14 of CD33 positiviteit Campylobacter
DNA bevatten, wat betekende dat myeloïde cellen of monocyten de Campylobacter DNA
bevattende cellen zijn. Deze resultaten gaven echter geen verklaring voor de in Hoofdstuk 5
gevonden T cel inactivatie bij GBS patiënten.
Een hypothese voor de opeenvolging van gebeurtenissen die tot GBS leidt en die gevestigde
ideeën combineert met nieuwe ontdekkingen zal nu volgen. Een infectie met een pathogeen dat
ganglioside-achtige epitopen draagt is de eerste gebeurtenis in de ontwikkeling van GBS. Er zal
eerst een normale immuunrespons volgen die bestaat uit een bacteriedodende of cytotoxische
aangeboren immuunrespons, gevolgd door een verworven immuunrespons bestaande uit
antilichaamproductie en T cel reactiviteit.
Om een tot nu toe onbekende reden wordt een subpopulatie van T cellen overgeactiveerd, gevolgd
door inactivatie, of een bepaalde T cel populatie was al inactief voordat de infectie tot stand
kwam. Als deze inactieve T cellen degene zijn die normaal gesproken regulerende T cellen
zouden moeten ondersteunen, of als zij zelf regulerende functies zouden moeten vervullen
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verandert de normale immuunrespons een pathogene die gekenmerkt wordt door een lange duur
en verhoogde intensiteit. Hierdoor worden pathogene antilichamen en immuunstimulerende
moleculen in grote hoeveelheden geproduceerd en komen zij in de perifere zenuw terecht waar
complement- en macrofaagactivatie tot zenuwschade leidt.
In dit scenario is moleculaire mimicry alleen niet voldoende om auto-immuniteit te veroorzaken,
maar het is wel een voorwaarde voor een pathogene respons. Slechts de combinatie van falende
immuunregulatie en een epitoop op een pathogeen dat op een epitoop op perifere zenuw lijkt leidt
tot GBS.
De vraag die meteen naar voren komt is naar de reden van inactivatie van T cellen. Mogelijke
antwoorden zijn: 1) de infectie is zeer ernstig wat komt door een eigenschap van het pathogeen
zelf, of 2) door onvoldoende afweer van de gastheer, wat beide leidt tot overactivatie en
inactivatie, of 3) genetische gastheerfactoren of 4) overige immunologische factoren dragen bij
aan T cel inactivatie. Het zou bijvoorbeeld van belang kunnen zijn welke immuunresponsen het
immuunsysteem van de gastheer al voortgebracht heeft voordat de GBS veroorzakende infectie
tot stand kwam.
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